Alexza Pharmaceuticals (ALXA) 10-K 28 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 23, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	ALXA
Entity Registrant Name	Alexza Pharmaceuticals Inc.
Entity Central Index Key	1,344,413
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		21,750,615
Entity Public Float			$ 18,482,850

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 7,755	$ 15,200
Marketable securities	0	19,574
Receivables	0	173
Inventory, net	0	3,729
Prepaid expenses and other current assets	3,237	3,109
Total current assets	10,992	41,785
Property and equipment, net	3,320	13,953
Restricted cash	0	2,757
Other assets	419	3,065
Total assets	14,731	61,560
Current liabilities:
Accounts payable	442	1,799
Accrued clinical trial liabilities	178	875
Other accrued liabilities	6,990	4,693
Current portion of contingent consideration liability	900	1,700
Financing obligations	46,840	0
Current portion of deferred revenues	2,848	2,450
Total current liabilities	58,198	11,517
Deferred rent	3,412	4,781
Noncurrent portion of contingent consideration liability	1,900	29,100
Noncurrent portion of deferred revenues	0	3,063
Noncurrent portion of financing obligations	21,127	63,767
Other noncurrent liabilities	$ 1,752	$ 985
Commitments and contingencies
Stockholders’ (deficit):
Preferred stock, $0.0001 par value, 5,000,000 shares authorized at December 31, 2015 and 2014; no shares issued and outstanding at December 31, 2015 or 2014	$ 0	$ 0
Common stock, $0.0001 par value; 200,000,000 shares authorized at December 31, 2015 and 2014, respectively; 19,577,729 and 19,404,697 shares issued and outstanding at December 31, 2015 and 2014, respectively	2	2
Additional paid-in capital	360,610	359,308
Accumulated other comprehensive (loss) income	0	(3)
Accumulated deficit	(432,270)	(410,960)
Total stockholders’ deficit	(71,658)	(51,653)
Total liabilities and stockholders’ deficit	$ 14,731	$ 61,560

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	19,577,729	19,404,697
Common stock, shares outstanding	19,577,729	19,404,697

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue
Collaboration revenue	$ 2,671	$ 2,997	$ 46,965
Product sales	2,355	2,564	874
Total revenues	5,026	5,561	47,839
Cost of goods sold	21,129	15,925	11,209
Research and development	11,716	13,748	19,082
General and administrative	12,205	13,344	15,778
Total operating expenses	45,050	43,017	46,069
Loss from operations	(40,024)	(37,456)	1,770
Change in fair value of contingent consideration liability	27,132	8,149	(39,913)
Interest and other income/expense, net	28	13	26
Interest expense	(8,446)	(7,438)	(1,498)
Net loss	(21,310)	(36,732)	(39,615)
Change in unrealized (loss) income on marketable securities	3	(4)	1
Comprehensive loss	$ (21,307)	$ (36,736)	$ (39,614)
Net loss per share - basic and diluted	$ (1.08)	$ (2.07)	$ (2.38)
Shares used to compute net loss per share - basic and diluted	19,810	17,784	16,669

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2012	$ 2,573	$ 2	$ 337,184		$ (334,613)
Beginning Balance, shares at Dec. 31, 2012		15,767,525
Issuance of common stock for cash	6,347		6,347
Issuance of common stock for cash, shares		1,437,481
Issuance of common stock under our Equity Incentive Plan	36		36
Issuance of common stock under our Equity Incentive Plan, shares		10,317
Issuance of common stock for cash under our Employee Stock Purchase Plan	200		200
Issuance of common stock for cash under our Employee Stock Purchase Plan, shares		54,494
Issuance of common stock upon vesting of restricted stock units		9,987
Compensation expense related to fair value of employee share based awards	3,371		3,371
Beneficial conversion feature of convertible debt	3,112		3,112
Change in unrealized (loss) income on marketable securities	1			$ 1
Net loss	(39,615)				(39,615)
Ending Balance at Dec. 31, 2013	(23,975)	$ 2	350,250	1	(374,228)
Ending Balance, shares at Dec. 31, 2013		17,279,804
Issuance of common stock for cash	5,600		5,600
Issuance of common stock for cash, shares		2,000,000
Issuance of common stock under our Equity Incentive Plan	79		79
Issuance of common stock under our Equity Incentive Plan, shares		22,842
Issuance of common stock for cash under our Employee Stock Purchase Plan	199		199
Issuance of common stock for cash under our Employee Stock Purchase Plan, shares		70,226
Issuance of common stock upon vesting of restricted stock units		31,825
Compensation expense related to fair value of employee share based awards	427		427
Beneficial conversion feature of convertible debt	1,032		1,032
Change in unrealized (loss) income on marketable securities	(4)			(4)
Net loss	(36,732)				(36,732)
Ending Balance at Dec. 31, 2014	(51,653)	$ 2	359,308	(3)	(410,960)
Ending Balance, shares at Dec. 31, 2014		19,404,697
Issuance of common stock warrant	1,721		1,721
Issuance of common stock for cash	$ 144		144
Issuance of common stock for cash, shares		125,000
Issuance of common stock under our Equity Incentive Plan, shares	0
Issuance of common stock for cash under our Employee Stock Purchase Plan	$ 38		38
Issuance of common stock for cash under our Employee Stock Purchase Plan, shares		26,157
Issuance of common stock upon vesting of restricted stock units		21,875
Compensation expense related to fair value of employee share based awards	1,120		1,120
Change in unrealized (loss) income on marketable securities	3			$ 3
Net loss	(21,310)				(21,310)
Ending Balance at Dec. 31, 2015	$ (71,658)	$ 2	$ 360,610		$ (432,270)
Ending Balance, shares at Dec. 31, 2015		19,577,729

Consolidated Statement of Cash

Consolidated Statement of Cash Flows	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Cash flows from operating activities:
Net loss	$ (21,310,000)	$ (36,732,000)	$ (39,615,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	1,120,000	427,000	3,371,000
Change in fair value of contingent consideration liability	(27,132,000)	(8,149,000)	39,913,000
Recognition of right to borrow asset			(2,800,000)
Amortization of debt discount and deferred interest	2,246,000	2,216,000	1,079,000
Amortization of discount on available-for-sale securities	81,000	163,000
Depreciation and amortization	3,001,000	3,393,000	3,323,000
Loss/(gain) on disposal of property and equipment		8,000	(15,000)
Impairment of property and equipment	8,591,000	0
Impairment of inventory	1,229,000
Impairment of prepaid expenses	1,024,000
Changes in operating assets and liabilities:
Receivables	173,000	(44,000)	(129,000)
Inventory	2,500,000	(282,000)	(3,447,000)
Prepaid expenses and other current assets	(1,152,000)	(822,000)	(601,000)
Other assets	1,812,000
Accounts payable	(1,357,000)	(1,990,000)	1,642,000
Accrued clinical trial expense and other accrued liabilities	558,000	654,000	1,122,000
Deferred revenues	(2,665,000)	413,000	(2,916,000)
Other liabilities	(602,000)	(754,000)	(1,539,000)
Net cash used in operating activities	(31,883,000)	(41,499,000)	(612,000)
Cash flows from investing activities:
Purchase of available-for-sale securities	(5,796,000)	(42,003,000)	(19,227,000)
Maturities of available-for-sale securities	25,292,000	30,840,000	10,650,000
Purchases of property and equipment	(58,000)	(2,363,000)	(1,784,000)
Proceeds from disposal of property and equipment	15,000		16,000
Net cash (used in) provided by investing activities	19,453,000	(13,526,000)	(10,345,000)
Cash flows from financing activities:
Proceeds from issuance of common stock, common stock warrants and exercise of stock options and stock purchase rights	182,000	5,878,000	6,583,000
Payment of contingent payment to Symphony Allegro Holdings, LLC	(868,000)	(251,000)	(10,313,000)
Change in restricted cash	2,757,000	(2,757,000)	5,051,000
Proceeds from financing obligations	2,914,000	50,830,000	15,000,000
Payments of financing obligations		(781,000)	(5,773,000)
Net cash provided by financing activities	4,985,000	52,919,000	10,548,000
Net decrease in cash and cash equivalents	(7,445,000)	(2,106,000)	(409,000)
Cash and cash equivalents at beginning of period	15,200,000	17,306,000
Cash and cash equivalents at end of period	7,755,000	15,200,000	17,306,000
Supplemental disclosures of cash flow information
Cash paid for interest	$ 2,757,000	4,169,000	863,000
Non cash investing and financing activities:
Debt discount related to Teva Note			4,405,000
Value of warrants issued with royalty securitization financing		1,721,000
Value of the beneficial conversion feature related to borrowing against Teva Note		$ 1,032,000	3,112,000
Value of right to borrow asset reclassified as debt discount			$ 2,800,000

The Company

The Company	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
The Company	1. The Company Business We were incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc., changed our name to Alexza Corporation in June 2001 and in December 2001 became Alexza Molecular Delivery Corporation. In July 2005, we changed our name to Alexza Pharmaceuticals, Inc. We are a pharmaceutical company focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. We operate in one business segment. Our facilities and employees are currently located in the United States. In 2012, we transitioned out of the development stage. Underwritten Public Offering On February 23, 2012, we issued an aggregate of 4,400,000 shares of our common stock and warrants to purchase up to an additional 4,400,000 shares of our common stock in an underwritten public offering. Net proceeds from the offering were $20,231,000, after deducting offering expenses. The warrants are exercisable beginning February 24, 2013, at an exercise price of $5.00 per share, and will expire on February 23, 2017. The shares of common stock and warrants were sold pursuant to a shelf registration statement declared effective by the Securities and Exchange Commission on May 20, 2010. We agreed to customary obligations, including indemnification. Private Placement On October 27, 2014 we entered into an amendment to the Collaboration, License and Supply Agreement dated October 5, 2011 Grupo Ferrer Internacional, S.A., or Ferrer, or the Ferrer Agreement, pursuant to which Ferrer and we agreed to eliminate future potential milestone payments in exchange for Ferrer’s purchase of $8,000,000 of our common stock, or the Ferrer Amendment. Ferrer purchased 2,000,000 shares of our common stock for $4.00 per share. We classified $2,400,000 of the proceeds as deferred revenue and we are recognizing the amount into revenue over the estimated performance period of the Ferrer Agreement. In September 2015, we issued a promissory note to Ferrer or the Ferrer Note. The terms of the Ferrer Note provide that (i) Ferrer will loan us up to $5,000,000 in tranches, (ii) the initial tranche of $3,000,000 was received by us on September 28, 2015, (iii) another tranche of $1,000,000 was received by us on March 21, 2016, (iv) we have the option to borrow an additional tranche of $1,000,000 at any time, (v) interest accrues on the outstanding principal at the rate of 6% per annum, compounded monthly, through May 31, 2016, (vi) all outstanding principal and accrued interest under the Ferrer Note is due and payable upon Ferrer’s demand on May 31, 2016, (vii) we may prepay the Ferrer Note at any time without premium or penalty, and (viii) we issued 125,000 shares of our common stock to Ferrer as partial consideration for the loan. The common stock was issued to Ferrer pursuant to the Stock Issuance Agreement and was not registered at the time of issuance under the Securities Act of 1933, as amended. As of March 23, 2016, an aggregate of $4,000,000 of the principal amount of the Ferrer Note was outstanding.

Need to Raise Additional Capita

Need to Raise Additional Capital	12 Months Ended
	Dec. 31, 2015
Text Block [Abstract]
Need to Raise Additional Capital	2. Need to Raise Additional Capital We have incurred significant losses from operations since inception and expect losses to continue for the foreseeable future. As of December 31, 2015, we had cash, cash equivalents, marketable securities and restricted cash (Refer to Note 3 - Summary of Significant Accounting Policies Financing Obligations We plan to finance our operations through partnership or licensing collaborations, the sale of equity securities, debt arrangements, a potential sale or disposition of one or more corporate assets or a strategic business combination or partnership, and we have engaged Guggenheim Securities, LLC to assist us in exploring such strategic options to enhance stockholder value. Such funding or potential transaction may not be available or may be on terms that are not favorable to us. Our inability to raise capital as and when needed could have a negative impact on our financial condition and our ability to continue as a going concern. If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock. Based on our available cash resources, the additional $1,000,000 drawn in March 2016 under the Ferrer Note (Refer to Note 8 - Financing Obligations Restructuring In February 2016, we entered into a definitive agreement with Teva whereby we reacquired the ADASUVE commercial U.S. rights and restructure our obligations under the outstanding Note from Teva. The agreement is intended to allow us to continue to provide ADASUVE product to patients and health care providers. The Amended Note with Teva, or the Amended Teva Note, provides that (i) we issue 2,172,886 shares of our common stock to Teva pursuant to a stock issuance agreement as consideration for a reduction in the outstanding balance of the Amended Teva Note by $5,000,000 and forgiveness of all accrued and unpaid interest under the Amended Teva Note; (ii) we are obligated to repay the remaining $20,000,000 outstanding balance of the Amended Teva Note in four annual consecutive payments of $5,000,000 beginning in the first calendar year following the calendar year in which the aggregate annual net sales of ADASUVE and any other Staccato enabled products first reach $50,000,000 in the United States; and (iii) we have ability to prepay the outstanding balance of the Amended Teva Note. We are further evaluating the impact of these changes on our consolidated financial position, results of operations and cash flows. The significant uncertainties surrounding any revenue from sales of ADASUVE, including royalties and milestone payments from our present and future collaborations, clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about our ability to continue as a going concern for a reasonable period of time. These consolidated financial statements have been prepared with the assumption that we will continue as a going concern and will be able to realize our assets and discharge our liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from our inability to continue as a going concern. In order to mitigate the risk related with this uncertainty, we plan to issue debt or additional shares of our common stock for cash and services or enter into additional collaborations or a strategic transaction during the next twelve months. There is no assurance we will able to raise sufficient capital on acceptable terms, or at all, to continue commercialization efforts for ADASUVE, continue development of our product candidates or to otherwise continue operations or that we will be able to execute any strategic transaction. Even if we are able to source additional capital, we may be forced to significantly reduce our operations if our business prospects do not improve. If we are unable to source additional capital, we may be forced to shut down operations altogether. In February 2016, we entered into the Letter of Intent with Ferrer with respect to the Transaction. The Letter of Intent does not constitute a binding agreement to consummate such acquisition and it entitles both us and Ferrer to terminate discussions at any time in our or Ferrer's sole discretion. Additionally we can, at our discretion, enter into discussions with third parties and continue to explore strategic options. We continue to have discussions with Ferrer regarding a transaction. There can be no assurance that such potential transaction will be agreed to or consummated. The entering into the Letter of Intent follows exploration of strategic options that we announced previously. In September 2015, we announced that we had retained Guggenheim Securities, LLC to assist in exploring strategic options to enhance stockholder value, including a possible sale or disposition of one or more corporate assets, a strategic business combination, partnership or other transactions. Our Board of Directors will review and carefully evaluate the terms of the potential Transaction with our financial and legal advisors.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Basis of Presentation We have prepared the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. Our fiscal year ends on December 31. The accompanying consolidated financial statements include our accounts and those of our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following: · Level 1 — Quoted prices in active markets for identical assets or liabilities. · Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. · Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) by major security type and contingent consideration liability measured at fair value on a recurring basis as of December 31, 2015 and 2014 (in thousands): December 31, 2015 Level 1 Level 2 Level 3 Total Assets Money market funds $ 6,806 $ — $ — $ 6,806 Corporate debt securities — — — — Total assets $ 6,806 $ — $ — $ 6,806 Liabilities Contingent consideration liability $ — $ — $ 2,800 $ 2,800 Total liabilities $ — $ — $ 2,800 $ 2,800 December 31, 2014 Level 1 Level 2 Level 3 Total Assets Money market funds $ 12,674 $ — $ — $ 12,674 Corporate debt securities — 24,617 — 24,617 Total assets $ 12,674 $ 24,617 $ — $ 37,291 Liabilities Contingent consideration liability $ — $ — $ 30,800 $ 30,800 Total liabilities $ — $ — $ 30,800 $ 30,800 Contingent Consideration Liability In connection with the exercise of our option to purchase all of the outstanding equity of Symphony Allegro, Inc., or Allegro, in 2009, we are obligated to make contingent cash payments to the former Allegro stockholders related to certain payments received by us from future collaboration agreements pertaining to ADASUVE/AZ-104 ( Staccato Staccato The projected cash flow assumptions for ADASUVE in the United States are based on internally and externally developed product sales forecasts. The timing and extent of the projected cash flows for ADASUVE for the territories licensed to Ferrer are based on the Ferrer Agreement (Refer to Note 8 – Financing Obligations We then assigned a probability to each of the cash flow scenarios based on several factors, including: the product candidate’s stage of development, preclinical and clinical results, technological risk related to the successful development of the different drug candidates, estimated market size, market risk and potential collaboration interest to determine a risk adjusted weighted average cash flow based on all of these scenarios. These probability and risk adjusted weighted average cash flows were then discounted utilizing our estimated weighted average cost of capital, or WACC. Our WACC considered our cash position, competition, risk of substitute products, and risk associated with the financing of the development projects. In 2013, we reduced the discount rate from 18.0% to 16.5% to reflect our then current estimated WACC. The change in discount rate increased the net loss for 2013 by approximately $3,600,000 or $0.22 per share. In 2014, we increased the discount rate from 16.5% to 20% to reflect our current estimated WACC. The change in discount rate decreased the net loss for 2014 by approximately $6,400,000 or $0.36 per share. The increase in our discount rate reflects the impact of our current financial condition, market capitalization and our estimated increase in borrowing costs. The fair value measurement of the contingent consideration liability is based on significant inputs not observed in the market and thus represents a Level 3 measurement. Level 3 measurements are valued based on unobservable inputs that are supported by little or no market activity and reflect our assumptions in measuring fair value. We record any changes in the fair value of the contingent consideration liability in earnings in the period of the change. Certain events including, but not limited to, the timing and terms of any collaboration agreement, clinical trial results, approval or non-approval of any future regulatory submissions and the commercial success of ADASUVE, AZ-104 or AZ-002 could have a material impact on the fair value of the contingent consideration liability, and as a result, our results of operations and financial position for the impacted period. During the fiscal year ended December 31, 2014, we modified the assumptions associated with the amount and timing of milestones and royalties projected for ADASUVE and AZ-002 and the probability that AZ-002 would be licensed or sold by us. These changes in assumptions, the change in the discount rate and the effects of the passage of a year on the present value computation resulted in a decrease to the net loss of $8,149,000, or $0.46 per share, for the fiscal year ended December 31, 2014. For the fiscal year ended December 31, 2015, we updated the discounted cash flow model to reflect the impact of our reacquisition of the U.S. commercial rights for ADASUVE from Teva by updating the U.S. ADASUVE sales estimates and partnership milestones and changing the probability weightings. Additionally, we updated the sales forecasts for the ADASUVE Ferrer Territories and changed the timing and amount of certain milestones for sales of ADASUVE outside of the United States and the Ferrer Territories and AZ-002. These changes resulted in our recognizing a non-operating, non-cash gain of $27,132,000, or $1.37 per share during the fiscal year ended December 31, 2015. A payment of $0.9 million was made during the first quarter of 2015 to the former Allegro stockholders. The following table represents a reconciliation of the change in the fair value measurement of the contingent consideration liability for the fiscal years ended December 31, 2015 and 2014 (in thousands): December 31, 2015 2014 (In thousands) Beginning balance $ 30,800 $ 39,200 Payments made (868 ) (251 ) Adjustments to fair value measurement (27,132 ) (8,149 ) Ending balance $ 2,800 $ 30,800 Financing Obligations We have estimated the fair value of our financing obligations (Refer to Note 8 – Financing Obligations At December 31, 2015 and 2014, the estimated fair value of our financing obligations was $52,151,000 and $52,075,000, respectively, and had book values of $67,967,000 and $63,767,000, respectively. Our payment commitments associated with these debt instruments may vary with changes in interest rates and are comprised of interest payments and principal payments. The estimated fair value of our debt will fluctuate with movements of interest rates, increasing in periods of declining rates of interest and declining in periods of increasing rates of interest. In addition, the fair value of our royalty securitization financing will be affected by the timing and amount of U.S. ADASUVE royalties and milestones. Concentration of Credit Risk Financial instruments that potentially subject us to credit risk consist of cash and cash equivalents to the extent of the amounts recorded on the balance sheets. Our cash and cash equivalents are placed with high credit-quality U.S. financial institutions and issuers. Cash Equivalents and Marketable Securities We determine the appropriate classification of our investments at the time of purchase. These securities are recorded as either cash equivalents or marketable securities. We consider all highly liquid investments with original maturities of three months or less from date of purchase to be cash equivalents. Cash equivalents consist of interest-bearing instruments including obligations of U.S. government agencies, high credit rating corporate borrowers and money market funds, which are carried at market value. All other investments are classified as available-for-sale marketable securities. We view our available-for-sale investments as available for use in current operations. Accordingly, we have classified all investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. Marketable securities are carried at estimated fair value with unrealized gains or losses included in accumulated other comprehensive income (loss) in stockholders’ (deficit) equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest and other income (expense), net. Realized gains and losses, if any, are also included in interest and other income (expense), net. The cost of all securities sold is based on the specific-identification method. Interest and dividends are included in interest income. We review our investments for other than temporary decreases in market value on a quarterly basis. To date, we have not recorded any charges related to other-than-temporary impairments. Restricted Cash In March 2014, from the proceeds from our royalty securitization financing (Refer to Note 7 – Commitments and Contingencies Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated life of the asset, generally three years for computer equipment, five years for manufacturing equipment and laboratory equipment, and seven years for furniture. Leasehold improvements are amortized over the estimated useful life or the remaining lease term, whichever is shorter. Impairment of Long-Lived Assets We review long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. During the fiscal year ended December 31, 2015, we evaluated the carrying values of our long-lived assets, principally our manufacturing and laboratory equipment and concluded that due to (i) the suspension of the ADASUVE commercial production operations during the third quarter of 2015, (ii) our continued operating losses and poor cash flows, (iii) the uncertainty of when we will resume commercial production, (iv) the limited ability to sell the capitalized equipment, and (v) our basic ability to continue as a going concern, the carrying amounts of our long-lived assets including the first and second manufacturing cells from Autoliv ASP, Inc., or Autoliv, exceeded their fair values based on a Level 3 fair value measurement. We recognized non-cash impairment charges of approximately $8,591,000 on our long-lived assets, $1,229,000 of related inventory with fixed expiration dates, and $1,024,000 on prepayments made to the supplier of our lower housing assembly for fiscal year 2015. We did not recognize any long-lived asset impairment during 2014. Revenue Recognition We recognize revenue when (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. Prior to the second quarter of 2013, our revenue consisted primarily of amounts earned from collaboration agreements and under research grants with the National Institutes of Health. Beginning in the second quarter of 2013, we also have revenue from product sales and beginning in the first quarter of 2014, we have royalty revenue. For collaboration agreements, revenues for non-refundable upfront license fee payments, where we continue to have performance obligations, are recognized as performance occurs and obligations are completed. Revenues for non-refundable upfront license fee payments where we do not have significant future performance obligations are recognized when the agreement is signed and the payments are due. For multiple element arrangements, such as collaboration agreements in which a collaborator may purchase several deliverables, we account for each deliverable as a separate unit of accounting if both of the following criteria are met: (i) the delivered item or items have value to the customer on a standalone basis; and (ii) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in our control. We evaluate how the consideration should be allocated among the units of accounting and allocate revenue to each non-contingent element based upon the relative selling price of each element. We determine the relative selling price for each deliverable using (i) vendor-specific objective evidence, or VSOE, of selling price if it exists; (ii) third-party evidence, or TPE, of selling price if it exists; or (iii) our best estimated selling price for that deliverable if neither VSOE nor TPE of selling price exists for that deliverable. We then recognize the revenue allocated to each element when the four basic revenue criteria described above are met for each element. For milestone payments received in connection with our collaboration agreements, we have elected to adopt the milestone method of accounting under Financial Accounting Standards Board Accounting Standards Codification 605-28, Milestone Method. Under the milestone method, revenues for payments which meet the definition of a milestone will be recognized as the respective milestones are achieved. We recognize product revenue as follows: · Persuasive Evidence of an Arrangement · Delivery · Sales Price Fixed or Determinable · Collectability Royalty revenue from our collaboration agreements is recognized as we receive information from our collaborators regarding product sales. Significant management judgment is used in the determination of revenue to be recognized and the period in which it is recognized. Inventory Inventory is stated at standard cost, which approximates actual cost, determined on a first-in first-out basis, not in excess of market value. Inventory includes the direct costs incurred to manufacture products combined with allocated manufacturing overhead, which consists of indirect costs, including labor and facility overhead. The carrying cost of inventory is reduced so as to not be in excess of the market value of the inventory as determined by the contractual transfer prices to Ferrer and Teva. The excess over the market value is expensed to cost of goods sold. If information becomes available that suggests that all or certain of the inventory may not be realizable, we may be required to expense a portion, or all, of the capitalized inventory into cost of goods sold. We have fulfilled all of the orders we received from Teva and Ferrer for commercial units of ADASUVE for the near and medium term. As a result, we have suspended our commercial production operations (Refer to Note 12 - Restructuring Our inventory as of December 31, 2015 and 2014, net of reserves, in thousands, is summarized as follows: December 31, 2015 2014 Raw materials $ — $ 3,677 Work in process — — Finished goods — 52 Total inventory $ — $ 3,729 Research and Development Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services. Research and development costs are expensed as incurred. Clinical development costs are a significant component of research and development expenses. We have a history of contracting with third parties that perform various clinical trial activities on our behalf in the ongoing development of our product candidates. The financial terms of these contracts are subject to negotiations and may vary from contract to contract and may result in uneven payment flow. We accrue and expense costs for clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with contract research organizations and clinical trial sites. We expect that research and development expenses will decrease during the fiscal year 2016 compared to 2015. We anticipate continuing to incur expenses related to our AZ-002 Phase 2a clinical trial, and, if financing is secured, expenses related to the clinical development of AZ-007. With the suspension of commercial ADASUVE production operations in the third quarter of 2015, a larger percentage of fixed overhead costs were allocated to research and development expenses, beginning in the fourth quarter of 2015. Income Taxes We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Share-Based Compensation Compensation cost for employee share-based awards is based on the grant-date fair value and is recognized on a ratable basis over the requisite service periods of the awards, which are generally the vesting periods. We issue employee share-based awards in the form of stock options and restricted stock units under our equity incentive plans and stock purchase rights under our employee stock purchase plan. Stock Options, Stock Purchase Rights and Restricted Stock Units During the fiscal years ended December 31, 2015, 2014 and 2013, the weighted average fair value per share of the employee stock options, restricted stock units and stock purchase rights granted were: 2015 2014 2013 Stock Options $ 0.80 $ 2.83 $ 3.46 Restricted Stock Units — — 4.67 Stock Purchase Rights 0.67 1.32 1.76 The estimated grant date fair values of the stock options and stock purchase rights were calculated using the Black-Scholes valuation model. The Black-Scholes model requires the use of a number of highly subjective and complex assumptions in determining the fair value of stock-based awards as follows: Weighted-Average Expected Term We determine the expected term of stock options granted through a combination of our own historical exercise experience and expected future exercise activities and post-vesting termination behavior. Under our 2005 Employee Stock Purchase Plan and our 2015 Employee Stock Purchase Plan, the expected term of employee stock purchase plan shares is equal to the offering period. Volatility We utilize our historical volatility to determine future volatility for the purpose of determining share-based payments for all options granted. Risk-Free Interest Rate We utilize U.S. Treasury zero-coupon issues with remaining terms similar to the expected term of the options or purchase rights on the respective grant dates to determine our risk-free interest rate. Dividend Yield We have never declared or paid any cash dividends and do not plan to pay cash dividends in the foreseeable future, and, therefore, use an expected dividend yield of zero in the valuation model. Forfeiture Rate We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. All stock-based payment awards are amortized on a straight-line basis over the requisite service periods of the awards, which are generally the vesting periods. During the fiscal years ended December 31, 2015, 2014 and 2013, we calculated the estimated grant date fair value of stock options and stock purchase rights using the following assumptions: 2015 2014 2013 Stock Option Plans Weighted-average expected term 5.0 Years 5.0 Years 5.0 Years Expected volatility 86% 83% 99% Risk-free interest rate 1.60% 1.66% 0.86% Dividend yield 0% 0% 0% Employee Stock Purchase Plan Weighted-average expected term 0.5 Years 0.5 Years 0.5 Years Expected volatility 87% 61% 80% Risk-free interest rate 0.19% 0.86% 0.70% Dividend yield 0% 0% 0% Restricted Stock Units The estimated fair value of restricted stock unit awards is calculated based on the market price of our common stock on the date of grant, reduced by the present value of dividends expected to be paid on our common stock prior to vesting of the restricted stock unit. Our estimate assumes no dividends will be paid prior to the vesting of the restricted stock unit. In 2013, certain restricted stock unit awards were issued that vest based on market conditions. The estimated fair value of these awards was calculated using a binomial lattice model with a term of 10 years, an expected volatility of 99.4%, a risk-free interest rate of 1.94% and a dividend yield of 0%. As of December 31, 2015, there were $1,725,000, $94,000 and $3,000 total unrecognized compensation costs, net of forfeiture, related to non-vested stock option awards, restricted stock unit awards and stock purchase rights, respectively, which are expected to be recognized over a weighted average period of 3.0 years, 1.1 years and 0.05 years, respectively. Recent Accounting Pronouncements In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under the current guidance. ASU 2014-15 is effective for us in the first quarter of 2016 with early adoption permitted. In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), that will supersede nearly all existing revenue recognition guidance under US GAAP. The core principle of the guidance is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. The standard will be effective for public entities for annual and interim periods beginning after December 15, 2017. Entities can choose to apply the standard using either the full retrospective approach or a modified retrospective approach. Entities electing the full retrospective adoption will apply the standard to each period presented in the financial statements. This means that entities will have to apply the new guidance as if it had been in effect since the inception of all its contracts with customers presented in the financial statements. Entities that elect the modified retrospective approach will apply the guidance retrospectively only to the most current period presented in the financial statements. This means that entities will have to recognize the cumulative effect of initially applying the new standard as an adjustment to the opening balance of retained earnings at the date of initial application. The new revenue standard will be applied to contracts that are in progress at the date of initial application. In July 2015, the Financial Accounting Standards Board issued ASU No. 2015-14, which delays the effective date of the standard for one year to annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. We are evaluating the requirements of this guidance and have not yet determined the impact of its adoption on our consolidated financial position, results of operations and cash flows. In April 2015, the Financial Accounting Standards Board issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In February 2016, the Financial Accounting Standards Board issued ASU 2016-02, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) -

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Net Loss per Share	4. Net Loss per Share Basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding for the period less weighted average shares subject to repurchase, of which there were none in 2015, 2014 or 2013. Outstanding stock options, warrants, and unvested restricted stock units are not included in the diluted net loss per share calculation for the fiscal years ended December 31, 2015, 2014 and 2013 as the inclusion of such shares would have had an anti-dilutive effect. Potentially anti-dilutive securities include the following (in thousands): Year Ended December 31, 2015 2014 2013 Outstanding stock options 2,130 2,429 1,657 Unvested restricted stock units 58 371 315 Warrants to purchase common stock 5,763 6,561 6,462 Convertible debt 5,499 4,803 651

Cash Equivalents and Marketable

Cash Equivalents and Marketable Securities	12 Months Ended
	Dec. 31, 2015
Cash And Cash Equivalents [Abstract]
Cash Equivalents and Marketable Securities	5. Cash Equivalents and Marketable Securities The amortized cost, fair value and unrealized gain/(loss) for our financial assets by major security type as of December 31, 2015 and 2014 are as follows (in thousands): Amortized Unrealized December 31, 2015 Cost Fair Value Gain/(Loss) Money market funds $ 6,806 $ 6,806 $ — Corporate debt securities — — — Total 6,806 6,806 — Less amounts classified as cash equivalents (6,806 ) (6,806 ) — Total marketable securities $ — $ — $ — Amortized Unrealized December 31, 2014 Cost Fair Value Gain/(Loss) Money market funds $ 12,674 $ 12,674 $ — Corporate debt securities 24,620 24,617 (3 ) Total 37,294 37,291 (3 ) Less amounts classified as cash equivalents (17,717 ) (17,717 ) — Total marketable securities $ 19,577 $ 19,574 $ (3 )

Balance Sheet Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Components	6. Balance Sheet Components Property and equipment consisted of the following (in thousands): December 31, 2015 2014 (In thousands) Lab equipment $ 1,369 $ 9,850 Manufacturing equipment — 11,239 Computer equipment and software 4,839 5,136 Furniture 774 816 Leasehold improvements 18,950 18,950 Property and equipment, gross 25,932 45,991 Less: accumulated depreciation (22,612 ) (32,038 ) Property and equipment, net $ 3,320 $ 13,953 Other accrued liabilities consisted of the following (in thousands): December 31, 2015 2014 (In thousands) Accrued interest $ 3,032 $ — Accrued compensation 2,035 2,781 Accrued capital project payment 916 — Accrued professional fees 569 1,144 Other 438 768 $ 6,990 $ 4,693

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Operating Leases We lease one building, at 2091 Stierlin Court, or the 2091 Building, in Mountain View, California, which we began to occupy in 2007. We recognize rental expense on the 2091 Building on a straight line basis over the initial term of the lease. Differences between the straight line rent expense and actual rent payments are classified as deferred rent liability on the balance sheet. The lease for the 2091 Building expires on March 31, 2018, and we have two options to extend the lease for five years each. The 2091 Building lease, as amended, includes tenant improvement reimbursements from the landlord. We have recorded all tenant improvements as additions to property and equipment and are amortizing the improvements over the shorter of the estimated useful life of the improvement or the remaining life of the lease. The reimbursements received from the landlord are included in deferred rent liability and amortized over the life of the lease as a contra-expense. Future minimum lease payments under non-cancelable operating leases, at December 31, 2015 were as follows (in thousands): Lease Payments 2016 $ 3,305 2017 3,386 2018 853 2019 — 2020 — Thereafter — Total minimum payments $ 7,544 Rental expense for the fiscal years ended December 31, 2015, 2014, and 2013 was $1,828,000, $1,953,000, $2,286,000, respectively. We had no rental income from the sublease agreements during the fiscal years ended December 31, 2015, 2014, or 2013. Manufacturing and Supply Agreement In November 2007, we entered into a manufacturing and supply agreement, or the Manufacture Agreement, with Autoliv , relating to the commercial supply of chemical heat packages that can be incorporated into our Staccato Subject to certain exceptions, Autoliv has agreed to manufacture, assemble and test the Chemical Heat Packages solely for us in conformance with our specifications. We pay Autoliv a specified purchase price, which varies based on annual quantities we order, per Chemical Heat Package delivered. Upon termination of the Manufacture Agreement, we were to retain full ownership of the production equipment for commercial manufacture of the Chemical Heat Packages developed for us by Autoliv, and Autoliv’s obligations under the Manufacture Agreement will terminate in full. In December 2014, we amended the Manufacture Agreement with Autoliv, or the 2014 Amendment through which we and Autoliv are extending the Manufacturing Agreement through 2018. In addition, we have the right to engage a second source supplier and implement a manufacturing line transfer from Autoliv to manufacture and supply the Chemical Heat Packages to us or our licensees. We have contracted with Autoliv, through a third-party supplier, to build one additional manufacturing cell to manufacture chemical heat packages at a cost of approximately $2,350,000, or the New Cell. The New Cell was expected to be installed at Autoliv with the cell currently being utilized by Autoliv, or the Original Cell, to be installed at a second source supplier. During the fiscal year ended December 31, 2015, we concluded that due to (i) the suspension of the ADASUVE commercial production operations during the third quarter of 2015, (ii) our continued operating losses and poor cash flows, (iii) the uncertainty of when we will resume commercial production, (iv) the limited ability to sell the capitalized equipment, and (v) our basic ability to continue as a going concern, the carrying amounts of our long-lived assets including the first and second manufacturing cells from Autoliv, exceeded their fair values based on a Level 3 fair value measurement. Accordingly, we recognized non-cash impairment charges of approximately $8,591,000 on our long-lived assets, $1,229,000 of related inventory with fixed expiration dates, and $1,024,000 on prepayments made to the supplier of our lower housing assembly for fiscal year 2015. We did not recognize any impairment charges during the fiscal year ended 2014. Contingencies From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings that arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No such provisions have been made for the periods presented herein. Litigation and related matters are inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of operations of that period or on our cash flows and liquidity.

Financing Obligations

Financing Obligations	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Financing Obligations	8. Financing Obligations Autoliv ASP, Inc. In June 2010, in return for transfer to us of all right, title and interest in a production line for the commercial manufacture of Chemical Heat Packages completed or to be completed by Autoliv on our behalf, we paid Autoliv $4,000,000 in cash and issued Autoliv a $4,000,000 unsecured promissory note. In February 2011, we entered into an agreement to amend the terms of the unsecured promissory note, or the Autoliv Note. Under the terms of the Autoliv Note, the original $4,000,000 note was cancelled and the Autoliv Note was issued with a reduced principal amount of $2,800,000. The Autoliv Note bore interest beginning on January 1, 2011 at 8% per annum and was paid in 48 consecutive and equal monthly installments of approximately $68,000. The Autoliv Note was paid in full in 2014. Teva Pharmaceuticals USA, Inc. In May 2013, concurrent with the Teva Agreement (refer to Note 9 – License Agreements At the time of the drawdowns, the contractual conversion price was less than the value of our common stock. As a result, at each draw down date, we calculated the value of the beneficial conversion feature of the convertible note and recorded an increase to additional paid-in-capital and a discount on the Teva Note which is being amortized to interest expense over the life of the borrowing. Additionally, at each draw, we reclassified the relative portion of the unamortized right-to-borrow asset, classified as an Other Asset, against the Teva Note, which is also being amortized to interest expense over the life of the borrowing. As we drew on the Teva Note, the relative portion of the unamortized right-to-borrow was accounted for as a discount on the borrowing and is being amortized to interest expense over the life of the borrowing. The following table shows the effective interest rate for each drawdown after taking into consideration the beneficial ownership features and the right-to-borrow asset discount. Reclassified Beneficial Unamortized Effective Draw Conversion Right-to- Interest Amount Feature Borrow Rate September 2013 $ 10,000,000 $ 2,455,000 $ 900,000 14.20 % December 2013 5,000,000 657,000 393,000 10.20 % March 2014 5,000,000 883,000 318,000 11.60 % June 2014 5,000,000 148,000 252,000 6.60 % We recognized $216,000 and $752,000 of interest expense related to amortization of the right-to-borrow asset during the fiscal years ended December 31, 2014 and 2013, respectively. As of December 31, 2014, all of the right-to-borrow asset had been reclassified against the Teva Note. In February 2016, we entered into an amendment to the Teva Note, or the Amended Teva Note, which provides that (i) we issue 2,172,886 shares of our common stock to Teva pursuant to a stock issuance agreement as consideration for a reduction in the outstanding balance of the Amended Teva Note by $5,000,000 and forgiveness of all accrued and unpaid interest under the Amended Teva Note; (ii) we are obligated to repay the remaining $20,000,000 outstanding balance of the Amended Teva Note in four annual consecutive payments of $5,000,000 beginning in the first calendar year following the calendar year in which the aggregate annual net sales of ADASUVE and any other Staccato enabled products first reach $50,000,000 in the United States; and (iii) we may prepay the outstanding balance of the Amended Teva Note. We are further evaluating the impact of these potential changes on our consolidated financial position, results of operations and cash flows. Royalty Securitization Financing In March 2014, we completed a royalty securitization financing, or the royalty securitization financing, which consisted of a private placement to qualified institutional investors of $45,000,000 of non-recourse notes issued by our wholly-owned subsidiary, or the Notes, and warrants to purchase 345,661 shares of our common stock at a price of $0.01 per share exercisable for five years from the date of issuance. The Notes bear interest at 12.25% per annum payable quarterly beginning June 15, 2014. All U.S. ADASUVE royalty and milestone payments under the Teva Agreement, after paying interest, administrative fees, and any applicable taxes, will be applied to principal and interest payments on the Notes until the Notes have been paid in full. From the proceeds of the transaction, we established a $6,890,000 interest reserve account, which is classified as a noncurrent asset, to cover any potential shortfall in interest payments. At December 31, 2014, $2,757,000 remained in the interest reserve account. The interest reserve account was fully utilized in 2015 to pay for interest related to our royalty securitization financing. In connection with our royalty securitization financing, we sold and contributed to our wholly-owned subsidiary all of our rights to U.S. ADASUVE royalty and milestone payments. The Notes are secured all of the assets of our subsidiary (including the right to receive royalty and milestone payments based on commercial sales of ADASUVE in the U.S.) and our equity ownership in the subsidiary. The Notes have no other recourse to us. The Notes may not be redeemed at our option until after March 18, 2016, and may be redeemed after that date subject to the achievement of certain milestones and the payment of a redemption premium for any redemption occurring prior to March 19, 2019. The Notes are not convertible into Alexza equity, nor have we guaranteed them. We valued the warrants issued to the Note holders utilizing the Black-Scholes valuation model with an assumed volatility of 87%, an estimated life of 5 years, a 1.54% risk-free interest rate and a dividend rate of 0%. The total value of the warrants, $1,721,000, was recognized as an increase to additional paid in capital and as a discount to the Notes. The Note discount is being amortized into interest expense over five-years. We incurred total fees and expenses of $4,171,000, which we recorded as a noncurrent Other Asset, and are amortizing into interest expense over a five-year period. In the fourth quarter of 2015, we did not make the quarterly interest payment due on December 15, 2015 for the Notes. As a result, we received a notice of event of default from the trustee. The aggregate interest payments that were in default were approximately $2,800,000, which includes the interest due and payable on September 15, 2015 and December 15, 2015. In January 2016, we entered into a forbearance agreement with the noteholders whereby the Noteholders would generally forbear from delivering an acceleration notice and exercising other remedies under the Notes for thirty day renewing periods through June 15, 2016. As a result of our default and the short forbearance time period, the principal balance of $45,000,000 and the amortization of the debt discounts of $74,000 related to the five-year warrants issued in connection with the royalty securitization financing were reclassified from non-current liabilities to current liabilities as of December 31, 2015. Additionally, the deferred interest charges associated with the royalty securitization financing that were being amortized over five years were reclassified from non-current assets to other current assets as of December 31, 2015, consistent with the related debt. Ferrer Promissory Note In September 2015, we issued the Ferrer Note to Ferrer. The terms of the Ferrer Note provide that (i) Ferrer will loan us up to $5,000,000 in tranches, ii) the initial tranche of $3,000,000 was received by us on September 28, 2015, (iii) another tranche of $1,000,000 was received by us on March 21, 2016, (iv) we have the option to borrow an additional tranche of $1,000,000 at any time, (v) interest accrues on the outstanding principal at the rate of 6% per annum, compounded monthly, through May 31, 2016, (vi) all outstanding principal and accrued interest under the Ferrer Note is due and payable upon Ferrer’s demand on May 31, 2016, (vii) we may prepay the Ferrer Note at any time without premium or penalty, and (viii) we issued 125,000 shares of our common stock to Ferrer as partial consideration for the loan. The common stock was issued to Ferrer pursuant to the Stock Issuance Agreement and was not registered at the time of issuance under the Securities Act of 1933, as amended. As of March 23, 2016, an aggregate of $4,000,000 of the principal amount of the Ferrer Note was outstanding. We valued the common stock issued to Ferrer at approximately $144,000 using the closing price of our common stock on the date we issued the stock to Ferrer. Based on the percent of the maximum principal amount of the Ferrer Note drawdown to date, 60% of the value of the common stock issued to Ferrer was proportionately recorded as a discount to the Ferrer Note and 40% was capitalized as a current asset on our consolidated Balance Sheet. As we drawdown any additional tranches, the remaining balance of the capitalized amount will be reclassified as a debt discount against the additional tranche. The amount of $144,000 is being amortized over the life of the Ferrer Note. The effective interest rate of the note, including the value of the shares issued, is 10.5%. Future scheduled principal payments under the debt obligations as of December 31, 2015 are as follows (in thousands): Total 2016 $ 3,000 2017 — 2018 — 2019 — Thereafter 25,000 Total $ 28,000 The above table excludes any payments pursuant to the $45,000,000 from the royalty securitization financing notes of our wholly-owned subsidiary, which have a legal maturity date in 2027. The principal payments by the subsidiary under the royalty securitization financing will be dependent upon the timing and amounts of royalties and milestone payments received under the Teva Agreement.

License Agreements

License Agreements	12 Months Ended
	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
License Agreements	9. License Agreements Grupo Ferrer Internacional, S.A. On October 5, 2011, we and Ferrer entered into the Ferrer Agreement to commercialize ADASUVE in the Ferrer Territories (Europe, Latin America, the Commonwealth of Independent States countries, the Middle East and North Africa countries, Korea, Philippines and Thailand). Under the terms of the Ferrer Agreement, we received an upfront cash payment of $10,000,000, of which $5,000,000 was paid to the former stockholders of Allegro. The Ferrer Agreement provided for up to an additional $51,000,000 in additional milestone payments, contingent on approval of the EU Marketing Authorization Application, or MAA, certain individual country commercial sales initiations and royalty payments based on cumulative net sales targets in the Ferrer Territories. The MAA was submitted to the European Medicines Agency, or EMA, and was approved in February 2013 by the European Commission, or the EC. Ferrer has the exclusive rights to commercialize the product in the Ferrer Territories. We supply ADASUVE to Ferrer for all of its commercial sales, and receive a specified per-unit transfer price paid in Euros. Either party may terminate the Ferrer Agreement for the other party’s uncured material breach or bankruptcy. The Ferrer Agreement continues in effect on a country-by-country basis until the later of the last to expire patent covering ADASUVE in such country or 12 years after first commercial sale. The Ferrer Agreement is subject to earlier termination in the event the parties mutually agree, by a party in the event of an uncured material breach by the other party or upon the bankruptcy or insolvency of either party. In October 2014, we entered into the Ferrer Amendment. We and Ferrer agreed to eliminate certain individual country commercial sales initiation milestone payments in exchange for Ferrer’s purchase of 2,000,000 shares of our common stock for $4.00 per share for a total of $8,000,000, which reflected a premium on the fair value of our common stock of approximately $2,400,000. In January 2015, we paid the former shareholders of Allegro $865,000 related to this stock sale. In June 2015, we entered into a second amendment to the Ferrer Agreement. We and Ferrer agreed to: (i) transfer ownership of the MAA to Ferrer, whereby Ferrer becomes responsible for all post-approval requirements of the MAA, including the post-authorization safety study, the drug utilization study and the Phase 3 clinical trial for adolescents and all other related regulatory activities and costs associated with the ADASUVE MAA, (ii) provide Ferrer an option to manufacture ADASUVE in the Ferrer Territories as well as for use by us in territories other than the U.S., Canada, China, Hong Kong, Taiwan and Macao, and if Ferrer does not exercise this option, we have the right to assign the ADASUVE manufacturing right to a third party, subject to Ferrer’s written consent, not to be unreasonably withheld, (iii) eliminate the remaining milestones related to first commercial sales in selected countries, and (iv) provide Ferrer with the right to access technology and develop a Staccato Staccato We evaluated whether the delivered elements under the Ferrer Agreement, as amended, have value on a stand-alone basis and allocated revenue to the identified units of accounting based on relative fair value. We determined that the license and the development and regulatory services are a single unit of accounting as the licenses were determined not to have stand-alone value. We have begun to deliver all elements of the arrangement and are recognizing the $10,000,000 upfront payment as revenue ratably over the estimated performance period of the agreement of four years. The $1,452,000 and $2,400,000 premiums received from the sales of common stock to Ferrer are additional consideration received pursuant to the Ferrer Agreement and does not pertain to a separate deliverable or element of the arrangement, and thus is being deferred and recognized as revenue in a manner consistent with the $10,000,000 upfront payment. The Ferrer Agreement, as amended, provides for us to receive up to $40,000,000 of additional payments related to cumulative net sales targets in the Ferrer Territories. The cumulative net sales targets will be recognized as royalty revenue when each target is earned and payable to us. We believe each of these milestones is substantive as there is uncertainty that the milestones will be met, the milestone can only be achieved as a result of our past performance and the achievement of the milestone will result in additional payment to us. In January 2014, we recognized revenue in the amount of $1,000,000 from a milestone payment for the first product sale in Spain, of which $250,000 was paid to the former stockholders of Allegro (Refer to Note 3 – Summary of Significant Accounting Policies We recognized $2,666,000, $1,987,000, and $2,915,000 of license revenue related to the Ferrer Agreement, as amended, in the years ended December 31, 2015, 2014, and 2013, respectively. At December 31, 2015 we had deferred revenue of $2,848,000 related to the Ferrer Agreement, as amended. Teva Pharmaceuticals USA, Inc. In May 2013, we entered into the Teva Agreement to provide Teva with an exclusive license to develop and commercialize ADASUVE in the United States. In February 2016, we entered into a definitive agreement with Teva whereby we reacquired the U.S. rights for ADASUVE and to restructure our obligations under the Teva Note, or the Teva Amendment. The Teva Amendment is intended to allow us to continue to provide ADASUVE product to patients and health care providers. In connection with the Teva Amendment we entered into the Amended Teva Note. The Amended Teva Note was considered additional consideration provided by Teva to us pursuant to the Teva Amendment. We evaluated whether the delivered elements under the Teva Agreement, as amended, have value on a stand-alone basis and allocated revenue to the identified units of accounting based on relative fair value. We determined that the license fees are a single unit of accounting and valued the license based on its best estimate of selling price, as VSOE and TPE of the selling price could not be determined. The selling price was estimated using discounted projected cash flows related to the licensed territory. We have delivered the license to Teva and recognized the $40,000,000 non-refundable upfront payment as revenue during 2013.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Warrants	10. Warrants In October 2009, we issued a total of 8,107,012 shares of our common stock and warrants to purchase up to an additional 7,296,312 shares of our common stock in a private placement. These securities were sold as units with each unit consisting of one share of common stock and a warrant to purchase 0.9 shares of common stock at a purchase price of $2.4325 per unit. The warrants issued are cash or net exercisable with an exercise price of $2.77 per share and will expire in October 2016. At December 31, 2015, 729,627 remained outstanding and exercisable. In May 2010, in conjunction with a Loan Agreement with Hercules Technology Growth Capital, or Hercules, we issued to Hercules a five-year warrant to purchase 37,639 shares of our common stock at a price of $26.90 per share. The warrant expired in May 2015. In August 2010, we issued an aggregate of 668,518 shares of our common stock and warrants to purchase up to an additional 334,258 shares of our common stock in a registered direct offering. These securities were sold as units with each unit consisting of (i) one share of common stock and (ii) a warrant to purchase 0.5 of a share of common stock, at a purchase price of $27.00 per unit. The warrants were exercisable at $33.00 per share and expired in August 2015. In May 2011, we issued an aggregate of 1,192,703 shares of our common stock and warrants to purchase up to an additional 417,445 shares of our common stock in a registered direct offering. The warrants are exercisable at $17.55 per share and will expire in May 2016. At December 31, 2015, these warrants remained outstanding and exercisable. In February 2012, we issued an aggregate of 4,400,000 shares of our common stock and warrants to purchase up to an additional 4,400,000 shares of our common stock in an underwritten public offering. The warrants are exercisable beginning February 24, 2013, at an exercise price of $5.00 per share, and will expire on February 23, 2017. At December 31, 2015, these warrants remained outstanding and exercisable. In March 2014, in conjunction with the royalty securitization financing, we issued to the debt holders a five-year warrant to purchase 345,661 shares of our common stock at a price of $0.01 per share. The warrant expires in March 2019. At December 31, 2015, these warrants remained outstanding and exercisable. All outstanding warrants include a provision that allows the warrant holder to net share settle the warrant. In no circumstances will we issue shares in excess of the number of shares underlying the warrant. The outstanding warrants are classified as additional paid in capital and are indexed to our common stock.

Equity Incentive Plans

Equity Incentive Plans	12 Months Ended
	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plans	11. Equity Incentive Plans 2005 Equity Incentive Plan In December 2005, our Board of Directors adopted the 2005 Equity Incentive Plan, or the 2005 Plan, and authorized for issuance thereunder 108,879 shares of common stock. The 2005 Plan became effective upon the closing of our initial public offering on March 8, 2006. The 2005 Plan is an amendment and restatement of our previous stock option plans. Stock options granted under the 2005 Plan generally vest over 4 years, vesting is generally based on service time, and have a maximum contractual term of 10 years. Restricted stock units granted to non-employee directors, which are granted in lieu of paying director fees in cash, generally vest one year after the date of grant. Prior to vesting, restricted stock units do not have dividend equivalent rights, do not have voting rights and the shares underlying the restricted units are not considered issued and outstanding. Shares are issued on the date the restricted stock units vest. The 2005 Plan provides for annual reserve increases on the first day of each fiscal year commencing on January 1, 2007 and ending on January 1, 2015. The annual reserve increases are equal to the lesser of (i) 2% of the total number of shares of our common stock outstanding on December 31 st 2005 Non-Employee Directors’ Stock Option Plan In December 2005, our Board of Directors adopted the 2005 Non-Employee Directors’ Stock Option Plan, or the Directors’ Plan, and authorized for issuance thereunder 25,000 shares of common stock. The Directors’ Plan provides for the automatic grant of non-statutory stock options to purchase shares of common stock to our non-employee directors, which vest over four years and have a term of 10 years. The Directors’ Plan provides for an annual reserve increase to be added on the first day of each fiscal year, commencing on January 1, 2007 and ending on January 1, 2015. The annual reserve increases are equal to the number of shares subject to options granted during the preceding fiscal year less the number of shares that revert back to the share reserve during the preceding fiscal year. Our Board of Directors has the authority to designate a smaller number of shares by which the authorized number of shares of common stock will be increased prior to the last day of any calendar year. In May 2013, our stockholders approved an amendment to the Directors’ Plan to increase the shares reserved by an additional 200,000 shares. 2015 Equity Incentive Plan In April 2015, our Board of Directors approved the 2015 Equity Incentive Plan, or the 2015 Plan, and authorized for issuance thereunder (i) an additional 1,000,000 shares of common stock plus (ii) the number of shares available for issuance pursuant to the grant of future awards under our 2005 Equity Incentive Plan determined as of the effective date of the 2015 Plan; plus (iii) the number of shares underlying outstanding stock awards granted under our previous stock option plans prior to the effective date of the 2015 Plan that expire or terminate for any reason prior to exercise or settlement, are forfeited or repurchased because of the failure to meet a contingency or condition required to vest such shares, or are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection with an award. The 2015 Plan became effective upon the approval of the plan by our stockholders on June 23, 2015. Due to the effectiveness of our 2015 Plan, no additional awards will be made under our previous stock option plans. All outstanding awards under our previous stock option plans will continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards and the terms of the applicable plan. Stock options issued under the 2015 Plan generally vest over 4 years; vesting is generally based on service time, and have a maximum contractual term of 10 years. 2015 Non-Employee Directors’ Stock Option Plan In April 2015, our Board of Directors adopted the 2015 Non-Employee Directors’ Stock Option Plan, or the 2015 Directors’ Plan, and authorized for issuance thereunder and (i) an additional 250,000 shares of common stock plus (ii) the number of shares available for issuance pursuant to the grant of future awards under our previous non-employee directors stock option plan determined as of the effective date of the 2015 Directors’ Plan; plus (iii) the number of shares underlying outstanding stock awards granted under our previous non-employee directors stock option plan prior to the effective date of the 2015 Directors’ Plan that expire or terminate for any reason prior to exercise or settlement, are forfeited or repurchased because of the failure to meet a contingency or condition required to vest such shares, or are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection with an award. The 2015 Directors’ Plan became effective upon the approval of the plan by our stockholders on June 23, 2015. Due to the effectiveness of our 2015 Directors’ Plan, no additional awards will be made under our previous non-employee directors’ stock option plan. The 2015 Directors’ Plan provides for the automatic grant of non-statutory stock options to purchase shares of common stock to our non-employee directors, which vest over approximately one year and have a term of 10 years. The following table sets forth the summary of option activity under our share-based compensation plans: Outstanding Options Number of Weighted Shares Exercise Price Balance as of January 1, 2015 1,978,273 $ 7.10 Options granted 1,544,300 1.19 Options exercised — — Options forfeited — — Options cancelled (1,196,172 ) 5.04 Balance as of December 31, 2015 2,326,401 4.23 At December 31, 2015, options to exercise 912,785 shares of our common stock, at a weighted average exercise price of $8.16 were exercisable. The intrinsic value of options exercised is calculated based on the difference between the exercise price and the quoted market price of our stock on the exercise date. The total intrinsic value of options exercised during the fiscal years ended December 31, 2014 and 2013 was $26,000, and $13,000, respectively. There were no exercises during the fiscal year ended December 31, 2015. Options to exercise 5,610 shares of our common stock expired in 2015. Information regarding the stock options outstanding at December 31, 2015 is summarized as follows: Outstanding Exercisable Remaining Remaining Contractual Aggregate Contractual Aggregate Number Life Intrinsic Number Life Intrinsic Exercise Price of Shares (In Years) Value of Shares (In Years) Value $0.88 - $0.88 18,000 9.97 $ — — — $ — $1.08 - $1.08 1,017,706 9.48 — 112,902 8.91 — $1.20 - $1.95 238,100 9.52 — 450 8.92 — $1.97 - $3.50 239,247 6.23 — 172,729 5.55 — $4.14 - $4.42 239,751 6.12 — 233,227 6.08 — $4.48 - $4.68 290,341 7.34 — 132,142 6.22 — $4.77 - $21.00 237,349 4.73 — 215,428 4.43 — $23.70 - $90.10 43,293 2.45 — 43,293 2.45 — $98.50 - $98.50 2,500 1.39 2,500 1.39 $117.00 - $117.00 114 1.01 — 114 1.01 — 2,326,401 7.92 $ — 912,785 5.78 $ — The intrinsic value noted in the table above is calculated as the difference between the market value per share as of December 31, 2015 and the exercise price of the shares. The market value per share as of December 31, 2015, the last trading date of 2015, was $0.70 as reported by The NASDAQ Stock Market. Information with respect to unvested share units (restricted stock units) as of December 31, 2015 is as follows: Weighted Number Average of Grant Date Shares Fair Value Outstanding at January 1, 2015 81,050 $ 4.67 Granted — — Released (21,875 ) 4.67 Forfeited (22,225 ) 4.67 Outstanding at December 31, 2015 36,950 4.67 The total value of restricted stock units released during the fiscal years ended December 31, 2015, 2014, and 2013 was $28,000, $136,000, and $75,000, respectively. We authorized shares of common stock for issuance under the 2005 Plan and the Directors’ Plan as follows. Year Number of Shares 2013 2,319,812 2014 158,751 2015 175,000 The shares authorized for issuance in 2013 include the annual reserve increase of 119,812 shares and the stockholder approved increase of 2,200,000 shares. As of December 31, 2014, 1,667,850 and 136,110 shares remained available for issuance under the 2005 Plan and the Directors’ Plan, respectively. The shares authorized for issuance in 2015 include the annual reserve increase of 175,000 shares. We authorized shares of common stock for issuance under the 2015 Plan and the 2015 Directors’ Plan as follows. Year Number of Shares 2015 1,250,000 The shares authorized for issuance include the stockholder approved increase of 1,250,000 shares. As of December 31, 2015, 2,503,057 and 400,000 shares remained available for issuance under the 2015 Plan and the 2015 Directors’ Plan, respectively. 2005 Employee Stock Purchase Plan In December 2005, our Board of Directors adopted the 2005 Employee Stock Purchase Plan, or the 2005 ESPP, and authorized for issuance thereunder 50,000 shares of common stock. The 2005 ESPP allows eligible employee participants to purchase shares of our common stock at a discount through payroll deductions. The 2005 ESPP consists of a fixed offering period, generally twenty-four months with four purchase periods within each offering period. Purchases are generally made on the last trading day of each October and April. Employees purchase shares at each purchase date at 85% of the market value of our common stock on their enrollment date or the end of the purchase period, whichever price is lower. The 2005 ESPP provides for annual reserve increases on the first day of each fiscal year commencing on January 1, 2007 and ending on January 1, 2015. The annual reserve increases will be equal to the lesser of (i) 1% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year, or (ii) 75,000 shares of common stock. Our Board of Directors has the authority to designate a smaller number of shares by which the authorized number of shares of common stock will be increased prior to the last day of any calendar year. In May 2011, our Compensation Committee terminated the then current offering period under the 2005 ESPP and resolved to begin a new offering period in August 2011 and also amended the 2005 ESPP to reduce the time period of each offering period from twenty-four to six months. In July 2011, following stockholder approval, the 2005 ESPP was amended to, among other changes, modify the annual automatic increase in shares reserved for the plan to an amount equal to the least of (i) one percent (1%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, (ii) 75,000 shares of common stock and (iii) an amount determined by our Board of Directors. 2015 Employee Stock Purchase Plan In April 2015, our Board of Directors adopted the 2015 Employee Stock Purchase Plan, or 2015 ESPP, and authorized for issuance thereunder (i) an additional 500,000 shares of our common stock plus (ii) the number of shares that remain available for issuance under the 2005 ESPP after all outstanding purchase rights under the 2005 ESPP are exercised. The 2015 ESPP allows eligible employee participants to purchase shares of our common stock at a discount through payroll deductions. The terms of any offering period under the 2015 ESPP will be determined by the Company’s board of directors, or the Board. Purchases are generally made on the last trading day of each November and May. Employees may purchase shares at each purchase date at 85% of the market value of our common stock at either the beginning of the offering period or the end of the purchase period, whichever price is lower. The 2005 ESPP remained in effect until the conclusion of our previous offering, which concluded in October 2015. There were 128,249 shares that were not purchased by our employees in the recently concluded offering under the 2005 ESPP and were added to the available reserve of 500,000 shares for the 2015 ESPP. Pursuant to the 2005 ESPP, on January 1, 2015, 2014 and 2013 an additional 75,000 shares for each year were reserved for issuance. We issued 26,157, 70,226, and 54,494 shares at weighted average prices of $1.46, $2.82, and $3.67 during the fiscal years ended December 31, 2015, 2014 and 2013, respectively. At December 31, 2015, 628,249 shares were available for issuance under the 2015 ESPP.

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2015
Restructuring And Related Activities [Abstract]
Restructuring	12. Restructuring As of December 31, 2015, we completed the commercial production and shipment of all ADASUVE orders received from Teva and Ferrer. With commercial production completed, we suspended our ADASUVE commercial manufacturing operations. During the fiscal year ended December 31, 2015, we concluded that due to (i) the suspension of the ADASUVE commercial production operations during the third quarter of 2015, (ii) our continued operating losses and poor cash flows, (iii) the uncertainty of when we will resume commercial production, (iv) the limited ability to sell the capitalized equipment, and (v) our basic ability to continue as a going concern, the carrying amounts of our long-lived assets including the first and second manufacturing cells from Autoliv ASP, Inc., or Autoliv, exceeded their fair values based on a Level 3 fair value measurement. We recognized non-cash impairment charges of approximately $8,591,000 on our long-lived assets, $1,229,000 of related inventory with fixed expiration dates, and $1,024,000 on prepayments made to the supplier of our lower housing assembly for fiscal year 2015. We did not record any long-lived asset impairment during 2014. As part of our restructuring plan, we eliminated 33 employees through the third quarter of 2015. Each affected employee received (i) severance payments equal to three months of salary plus an additional amount equal to one week of salary for each year of Alexza service in excess of five years; and (ii) three months of paid medical insurance premiums and outplacement services, or in total, the Severance Package. In addition, the majority of our remaining employees have received notification that their positions may be eliminated. If we are unable to obtain additional financing and further restructure our operations, the remaining employees who received notification will receive benefits substantially equivalent to the Severance Package. The aggregate cost of the Severance Package for these employees is being amortized over the period in which the employees are expected to provide service. During the fiscal year 2015, we recognized $2,718,000 of severance related expenses and none in 2014 and 2013, which is recorded in accrued compensation as of December 31, 2015. We have accrued $1,474,000 in severance related expenses.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Event	13. Subsequent Events We did not make the quarterly interest payment due on December 15, 2015 for the royalty securitization financing. As a result, we received a notice of event of default from the trustee. The aggregate interest payments that were in default were approximately $2,756,000, which includes the interest due and payable on September 15, 2015 and December 15, 2015. In January 2016, we entered into a forbearance agreement with the noteholders whereby the Noteholders would generally forbear from delivering an acceleration notice and exercising other remedies under the agreement for thirty day renewing periods through June 15, 2016. As a result of our default and the short forbearance time period, the principal balance of $45,000,000 and the amortization of the debt discounts of $74,000 related to the five-year warrants issued in March 2014 to purchase 345,661 shares of our common stock were reclassified from non-current liabilities to current liabilities as of December 31, 2015. Additionally, the deferred interest charges associated with this financing that were being amortized over five years were reclassified from non-current assets to other current assets as of December 31, 2015, consistent with the related debt. In January 2016, Ferrer exercised its option to manufacture and supply ADASUVE in their exclusive territory, outside their territory in all countries other than the U.S. and Canada, and in the U.S. and Canada in a manner to be agreed in a definitive agreement by April 2016. We are evaluating the impact of these potential changes on our consolidated financial position, results of operations and cash flows. In February 2016, we entered into the non-binding Letter of Intent with Ferrer with respect to the Transaction. The Letter of Intent does not constitute a binding agreement to consummate such acquisition and it entitles both us and Ferrer to terminate discussions at any time in our or Ferrer's sole discretion. Additionally we can, at our discretion, enter into discussions with third parties and continue to explore strategic options. We continue to have discussions with Ferrer regarding a transaction. There can be no assurance that such potential transaction will be agreed to or consummated. The entering into the Letter of Intent follows exploration of strategic options that we announced previously. In September 2015, we announced that we had retained Guggenheim Securities, LLC to assist in exploring strategic options to enhance stockholder value, including a possible sale or disposition of one or more corporate assets, a strategic business combination, partnership or other transactions. Our Board of Directors will review and carefully evaluate the terms of the potential Transaction with our financial and legal advisors. In September 2015, we issued the Ferrer Note to Ferrer. The terms of the Ferrer Note provide that (i) Ferrer will loan us up to $5,000,000 in tranches, (ii) the initial tranche of $3,000,000 was received by us on September 28, 2015, (iii) another tranche of $1,000,000 was received by us on March 21, 2016, (iv) we have the option to borrow an additional tranche of $1,000,000 at any time, (v) interest accrues on the outstanding principal at the rate of 6% per annum, compounded monthly, through May 31, 2016, (vi) all outstanding principal and accrued interest under the Ferrer Note is due and payable upon Ferrer’s demand on May 31, 2016, (vii) we may prepay the Ferrer Note at any time without premium or penalty, and (viii) we issued 125,000 shares of our common stock to Ferrer as partial consideration for the loan. The common stock was issued to Ferrer pursuant to the Stock Issuance Agreement and was not registered at the time of issuance under the Securities Act of 1933, as amended. As of March 23, 2016, an aggregate of $4,000,000 of the principal amount of the Ferrer Note was outstanding. In February 2016, we and Teva entered into (i) the Teva Amendment; (ii) the Amended Teva Note; (iii) a stock issuance agreement, or the Stock Issuance Agreement; and (iv) an Amended and Restated Registration Rights Agreement, or the Rights Agreement, that amends and restates the Registration Rights Agreement with Teva dated January 6, 2014. The Teva Amendment is intended to allow us to continue to provide ADASUVE product to patients and health care providers and provides for (i) the transfer of the New Drug Application, or NDA, and related regulatory filings for ADASUVE to us and the assumption of responsibility by us for all regulatory activities related to ADASUVE in the U.S. as soon as practicable; (ii) an exclusive license of Teva intellectual property with respect to ADASUVE, which intellectual property will be assigned to us in connection with a change of control or an exclusive license to ADASUVE in the U.S. from us to a third party; (iii) our undertaking of responsibility for the ADASUVE United States Phase 4 study, product pharmacovigilance, medical services, and REMS compliance, either through Teva’s vendors or a vendor otherwise selected by us; (iv) the transfer from Teva of existing supplies of ADASUVE as well as all commercial, medical and academic materials, documents and relationships; (v) our right to sell Teva-labeled products in accordance with all applicable laws and Teva policies; (vi) the satisfaction and termination of all payment obligations of the parties with respect to the commercialization of ADASUVE except with respect to the Amended Teva Note and our issuance of 2,172,886 shares of our common stock to Teva pursuant to the Stock Issuance Agreement; and (vii) a mutual release between the parties with respect to claims under the Teva Agreement. The Amended Teva Note provides that (i) we issued 2,172,886 shares of our common stock to Teva pursuant to a stock issuance agreement as consideration for a reduction in the outstanding balance of the Amended Teva Note by $5,000,000 and forgiveness of all accrued and unpaid interest under the Amended Teva Note; (ii) we are obligated to repay the $20,000,000 outstanding balance of the Amended Teva Note in four annual consecutive payments of $5,000,000 beginning in the first calendar year following the calendar year in which the aggregate annual net sales of ADASUVE and any other Staccato enabled products first reach $50,000,000 in the United States; and (iii) we may prepay the outstanding balance of the Amended Teva Note. We are further evaluating the impact of these potential changes on our consolidated financial position, results of operations and cash flows. The shares of our common stock were issued to Teva in accordance with the terms of the Amended Note and the related Stock Issuance Agreement as partial consideration for a reduction in the outstanding balance of the Amended Teva Note by $5,000,000 and forgiveness of all accrued and unpaid interest under the Amended Teva Note. The shares of our common stock issued to Teva pursuant to the Stock Issuance Agreement were not registered at the time of issuance under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements, but the Company has agreed to provide certain registration rights under the Securities Act with respect to the Shares pursuant to the Rights Agreement. In February 2016, we presented a plan to the NASDAQ’s Listing Qualification Panel, or the Panel, for determination to allow the continued listing our common stock on the NASDAQ Capital Market. On March 7, 2016, the Panel issued a determination granting our request for the continued listing of our common stock on The NASDAQ Capital Market. Our continued listing on The NASDAQ Capital Market is subject to, among other things, evidence of our compliance with the minimum $35,000,000 market value of listed securities requirement by June 14, 2016. In order to satisfy the market value of listed securities requirement, we

401(k) Plan

401(k) Plan	12 Months Ended
	Dec. 31, 2015
Compensation And Retirement Disclosure [Abstract]
401(k) Plan	14. 401(k) Plan We sponsor a 401(k) Plan that stipulates that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations. During the fiscal years ended December 31, 2015 and 2014, we matched a total of $36,000 and $128,000 employee contributions, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes There is no provision for income taxes because we have incurred operating losses since inception and applied a full valuation allowance against all deferred tax assets. The reported amount of income tax expense (benefit) attributable to operations for the year differs from the amount that would result from applying domestic federal statutory tax rates to loss before income taxes from operations as summarized below (in thousands): Year Ended December 31, 2015 2014 2013 Federal tax benefit at statutory rate $ (7,246 ) $ (12,489 ) $ (13,469 ) State tax benefit net of federal effect (1,243 ) (2,143 ) (2,311 ) Research and development credits (456 ) (560 ) (532 ) Other permanent differences 8 2 14 Share-based compensation 678 414 650 Adjustment to basis in subsidiary (10,808 ) (3,246 ) 15,899 Change in valuation allowance 17,140 16,946 (357 ) Reduction of deferred tax asset attributed to expired net operating loss carryforward 1,927 1,076 106 Other — — — Total $ — $ — $ — Deferred income taxes reflect the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amount used for income tax purposes. The deferred tax assets were calculated using an effective tax rate of 40%. Significant components of our deferred tax assets are as follows (in thousands): December 31, 2015 2014 Federal and state net operating loss carryforwards $ 139,874 $ 130,011 Federal and state research and development credit carryforwards 16,222 15,536 Accrued liabilities 3,460 7,177 Properties and Equipment 7,740 — Capitalized research and development costs 16,263 16,027 Other 1,842 2,092 Total deferred tax assets 185,401 170,843 Valuation allowance (185,401 ) (170,843 ) Net deferred tax assets $ — $ — Our accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of our net deferred tax assets. We primarily considered such factors as our history of operating losses, the nature of our deferred tax assets and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At present, we do not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance has been established and no deferred tax asset is shown in the accompanying balance sheets. The valuation allowance (decreased) increased by approximately $14,558,000, $16,645,000, and $(272,000) during the fiscal years ended December 31, 2015, 2014 and 2013, respectively. As of December 31, 2015 we had federal net operating loss carryforwards of approximately $368,164,000. We also had federal research and development tax credit carryforwards of approximately $10,731,000. The net operating loss and tax credit carryforwards will expire at various dates beginning in 2020, if not utilized. As of December 31, 2015, we had state net operating loss carryforwards of approximately $261,431,000 which will begin to expire in 2016. We also had state research and development tax credit carryforwards of approximately $8,319,000, which have no expiration. As of December 31, 2015, approximately $1,393,000 of federal and state net operating loss is attributable to stock-based compensation deductions in excess of book expense. When realized, the benefit of the tax deduction related to these options will be accounted for as a credit to stockholders’ equity rather than as a reduction of the income tax provision. A limitation may apply to the use of the net operating loss and credit carryforwards, under provisions of the Internal Revenue Code that are applicable if we experience an “ownership change”. That may occur, for example, as a result of trading in our stock by institutional investors as well issuance of new equity. Should these limitations apply, the carryforwards would be subject to an annual limitation, resulting in a substantial reduction in the gross deferred tax assets before considering the valuation allowance. As of December 31, 2015, we have not performed an analysis to determine if our net operating loss and credit carryforwards would be subject to such limitations. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Balance at January 1, 2013 $ 3,014 Additions based on tax positions taken during a prior period — Reductions based on tax positions taken during a prior period (231 ) Additions based on tax positions taken during the current period 36 Reductions based on tax positions taken during the current period — Reductions related to settlement of tax matters — Reductions related to a lapse of applicable statute of limitations — Balance at December 31, 2013 2,819 Additions based on tax positions taken during a prior period — Reductions based on tax positions taken during a prior period — Additions based on tax positions taken during the current period 113 Reductions based on tax positions taken during the current period — Reductions related to settlement of tax matters — Reductions related to a lapse of applicable statute of limitations — Balance at December 31, 2014 2,932 Additions based on tax positions taken during a prior period 87 Reductions based on tax positions taken during a prior period — Additions based on tax positions taken during the current period 95 Reductions based on tax positions taken during the current period — Reductions related to settlement of tax matters — Reductions related to a lapse of applicable statute of limitations — Balance at December 31, 2015 $ 3,114 If we eventually are able to recognize these uncertain tax positions, the unrecognized tax benefits would not reduce the effective tax rate if we are applying a full valuation allowance against the deferred tax assets, as is our current policy. We have not incurred any material tax interest or penalties as of December 31, 2015. We do not anticipate any significant change within twelve months of this reporting date of its uncertain tax positions. We are subject to taxation in the United States and various states jurisdictions. There are no other ongoing examinations by taxing authorities at this time. Our various tax years starting with 2000 to 2015 remain open in various taxing jurisdictions.

Quarterly Results

Quarterly Results	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results	16. Quarterly Results (Unaudited) The following table is in thousands, except per share amounts: Quarter Ended March 31 June 30 September 30 December 31 Fiscal 2015 Revenues $ 705 $ 1,875 $ 1,773 $ 673 Loss from operations (13,003 ) (9,441 ) (7,597 ) (9,983 ) Net loss (404 ) (12,450 ) (5,438 ) (3,018 ) Basic and diluted net loss per share (0.02 ) (0.63 ) (0.27 ) (0.15 ) Fiscal 2014 Revenues $ 2,166 $ 1,484 $ 457 $ 1,454 Loss from operations (8,803 ) (11,349 ) (10,040 ) (7,264 ) Net loss (10,735 ) (5,962 ) (13,328 ) (6,707 ) Basic and diluted net loss per share (0.62 ) (0.34 ) (0.77 ) (0.35 ) During the quarter ended December 31, 2014, we reversed approximately $1,009,000 and $1,191,000 of share-based compensation that was recognized during the three quarters ended September 31, 2014 and the three years ended December 31, 2013, respectively, due to a reversal of share-based compensation related to the rescission of equity awards. During the fiscal year ended December 31, 2015, we concluded that the carrying amounts of our production-related long-lived assets, inventory, and prepayments exceeded their fair values given our continued operating losses, the uncertainty of when we will resume commercial production, the limited ability to sell the capitalized equipment, and our basic ability to continue as a going concern. We recognized non-cash impairment charges in the aggregate amount of $10,844,000. These were offset by the change in the fair value of our contingent consideration liability to the former stockholders of Allegro based on various assumptions. During the fourth quarter of 2015, we updated the discounted cash flow model used to calculate the contingent consideration liability to reflect the impact of our reacquisition of the U.S. commercial rights for ADASUVE from Teva. These changes include updating the US ADASUVE sales estimates and partnership milestones and changing the probability weightings. Additionally, we updated the sales for the ADASUVE Ferrer Territories and changed the timing and amount of certain milestones for sales of ADASUVE outside of the United States and the Ferrer Territories and AZ-002. These changes resulted in our recognizing a non-operating, non-cash gain of $27,132,000 during the fiscal year ended December 31, 2015. We also reduced our headcount in 2015 due to the decision to suspend our commercial production thus, giving rise to decreased salaries and related benefits during the fiscal year ended December 31, 2015.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Need to Raise Additional Capital	We have incurred significant losses from operations since inception and expect losses to continue for the foreseeable future. As of December 31, 2015, we had cash, cash equivalents, marketable securities and restricted cash (Refer to Note 3 - Summary of Significant Accounting Policies Financing Obligations
Basis of Presentation	Basis of Presentation We have prepared the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. Our fiscal year ends on December 31. The accompanying consolidated financial statements include our accounts and those of our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following: · Level 1 — Quoted prices in active markets for identical assets or liabilities. · Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. · Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Contingent Consideration Liability	Contingent Consideration Liability In connection with the exercise of our option to purchase all of the outstanding equity of Symphony Allegro, Inc., or Allegro, in 2009, we are obligated to make contingent cash payments to the former Allegro stockholders related to certain payments received by us from future collaboration agreements pertaining to ADASUVE/AZ-104 ( Staccato Staccato The projected cash flow assumptions for ADASUVE in the United States are based on internally and externally developed product sales forecasts. The timing and extent of the projected cash flows for ADASUVE for the territories licensed to Ferrer are based on the Ferrer Agreement (Refer to Note 8 – Financing Obligations We then assigned a probability to each of the cash flow scenarios based on several factors, including: the product candidate’s stage of development, preclinical and clinical results, technological risk related to the successful development of the different drug candidates, estimated market size, market risk and potential collaboration interest to determine a risk adjusted weighted average cash flow based on all of these scenarios. These probability and risk adjusted weighted average cash flows were then discounted utilizing our estimated weighted average cost of capital, or WACC. Our WACC considered our cash position, competition, risk of substitute products, and risk associated with the financing of the development projects. In 2013, we reduced the discount rate from 18.0% to 16.5% to reflect our then current estimated WACC. The change in discount rate increased the net loss for 2013 by approximately $3,600,000 or $0.22 per share. In 2014, we increased the discount rate from 16.5% to 20% to reflect our current estimated WACC. The change in discount rate decreased the net loss for 2014 by approximately $6,400,000 or $0.36 per share. The increase in our discount rate reflects the impact of our current financial condition, market capitalization and our estimated increase in borrowing costs. The fair value measurement of the contingent consideration liability is based on significant inputs not observed in the market and thus represents a Level 3 measurement. Level 3 measurements are valued based on unobservable inputs that are supported by little or no market activity and reflect our assumptions in measuring fair value. We record any changes in the fair value of the contingent consideration liability in earnings in the period of the change. Certain events including, but not limited to, the timing and terms of any collaboration agreement, clinical trial results, approval or non-approval of any future regulatory submissions and the commercial success of ADASUVE, AZ-104 or AZ-002 could have a material impact on the fair value of the contingent consideration liability, and as a result, our results of operations and financial position for the impacted period.
Financing Obligations	Financing Obligations We have estimated the fair value of our financing obligations (Refer to Note 8 – Financing Obligations At December 31, 2015 and 2014, the estimated fair value of our financing obligations was $52,151,000 and $52,075,000, respectively, and had book values of $67,967,000 and $63,767,000, respectively. Our payment commitments associated with these debt instruments may vary with changes in interest rates and are comprised of interest payments and principal payments. The estimated fair value of our debt will fluctuate with movements of interest rates, increasing in periods of declining rates of interest and declining in periods of increasing rates of interest. In addition, the fair value of our royalty securitization financing will be affected by the timing and amount of U.S. ADASUVE royalties and milestones.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject us to credit risk consist of cash and cash equivalents to the extent of the amounts recorded on the balance sheets. Our cash and cash equivalents are placed with high credit-quality U.S. financial institutions and issuers.
Cash Equivalents and Marketable Securities	Cash Equivalents and Marketable Securities We determine the appropriate classification of our investments at the time of purchase. These securities are recorded as either cash equivalents or marketable securities. We consider all highly liquid investments with original maturities of three months or less from date of purchase to be cash equivalents. Cash equivalents consist of interest-bearing instruments including obligations of U.S. government agencies, high credit rating corporate borrowers and money market funds, which are carried at market value. All other investments are classified as available-for-sale marketable securities. We view our available-for-sale investments as available for use in current operations. Accordingly, we have classified all investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. Marketable securities are carried at estimated fair value with unrealized gains or losses included in accumulated other comprehensive income (loss) in stockholders’ (deficit) equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest and other income (expense), net. Realized gains and losses, if any, are also included in interest and other income (expense), net. The cost of all securities sold is based on the specific-identification method. Interest and dividends are included in interest income. We review our investments for other than temporary decreases in market value on a quarterly basis. To date, we have not recorded any charges related to other-than-temporary impairments.
Restricted Cash	Restricted Cash In March 2014, from the proceeds from our royalty securitization financing (Refer to Note 7 – Commitments and Contingencies
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated life of the asset, generally three years for computer equipment, five years for manufacturing equipment and laboratory equipment, and seven years for furniture. Leasehold improvements are amortized over the estimated useful life or the remaining lease term, whichever is shorter.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets We review long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. During the fiscal year ended December 31, 2015, we evaluated the carrying values of our long-lived assets, principally our manufacturing and laboratory equipment and concluded that due to (i) the suspension of the ADASUVE commercial production operations during the third quarter of 2015, (ii) our continued operating losses and poor cash flows, (iii) the uncertainty of when we will resume commercial production, (iv) the limited ability to sell the capitalized equipment, and (v) our basic ability to continue as a going concern, the carrying amounts of our long-lived assets including the first and second manufacturing cells from Autoliv ASP, Inc., or Autoliv, exceeded their fair values based on a Level 3 fair value measurement. We recognized non-cash impairment charges of approximately $8,591,000 on our long-lived assets, $1,229,000 of related inventory with fixed expiration dates, and $1,024,000 on prepayments made to the supplier of our lower housing assembly for fiscal year 2015. We did not recognize any long-lived asset impairment during 2014.
Revenue Recognition	Revenue Recognition We recognize revenue when (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. Prior to the second quarter of 2013, our revenue consisted primarily of amounts earned from collaboration agreements and under research grants with the National Institutes of Health. Beginning in the second quarter of 2013, we also have revenue from product sales and beginning in the first quarter of 2014, we have royalty revenue. For collaboration agreements, revenues for non-refundable upfront license fee payments, where we continue to have performance obligations, are recognized as performance occurs and obligations are completed. Revenues for non-refundable upfront license fee payments where we do not have significant future performance obligations are recognized when the agreement is signed and the payments are due. For multiple element arrangements, such as collaboration agreements in which a collaborator may purchase several deliverables, we account for each deliverable as a separate unit of accounting if both of the following criteria are met: (i) the delivered item or items have value to the customer on a standalone basis; and (ii) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in our control. We evaluate how the consideration should be allocated among the units of accounting and allocate revenue to each non-contingent element based upon the relative selling price of each element. We determine the relative selling price for each deliverable using (i) vendor-specific objective evidence, or VSOE, of selling price if it exists; (ii) third-party evidence, or TPE, of selling price if it exists; or (iii) our best estimated selling price for that deliverable if neither VSOE nor TPE of selling price exists for that deliverable. We then recognize the revenue allocated to each element when the four basic revenue criteria described above are met for each element. For milestone payments received in connection with our collaboration agreements, we have elected to adopt the milestone method of accounting under Financial Accounting Standards Board Accounting Standards Codification 605-28, Milestone Method. Under the milestone method, revenues for payments which meet the definition of a milestone will be recognized as the respective milestones are achieved. We recognize product revenue as follows: · Persuasive Evidence of an Arrangement · Delivery · Sales Price Fixed or Determinable · Collectability Royalty revenue from our collaboration agreements is recognized as we receive information from our collaborators regarding product sales. Significant management judgment is used in the determination of revenue to be recognized and the period in which it is recognized.
Inventory	Inventory Inventory is stated at standard cost, which approximates actual cost, determined on a first-in first-out basis, not in excess of market value. Inventory includes the direct costs incurred to manufacture products combined with allocated manufacturing overhead, which consists of indirect costs, including labor and facility overhead. The carrying cost of inventory is reduced so as to not be in excess of the market value of the inventory as determined by the contractual transfer prices to Ferrer and Teva. The excess over the market value is expensed to cost of goods sold. If information becomes available that suggests that all or certain of the inventory may not be realizable, we may be required to expense a portion, or all, of the capitalized inventory into cost of goods sold.
Research and Development	Research and Development Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services. Research and development costs are expensed as incurred. Clinical development costs are a significant component of research and development expenses. We have a history of contracting with third parties that perform various clinical trial activities on our behalf in the ongoing development of our product candidates. The financial terms of these contracts are subject to negotiations and may vary from contract to contract and may result in uneven payment flow. We accrue and expense costs for clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with contract research organizations and clinical trial sites. We expect that research and development expenses will decrease during the fiscal year 2016 compared to 2015. We anticipate continuing to incur expenses related to our AZ-002 Phase 2a clinical trial, and, if financing is secured, expenses related to the clinical development of AZ-007. With the suspension of commercial ADASUVE production operations in the third quarter of 2015, a larger percentage of fixed overhead costs were allocated to research and development expenses, beginning in the fourth quarter of 2015.
Income Taxes	Income Taxes We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Share-Based Compensation	Share-Based Compensation Compensation cost for employee share-based awards is based on the grant-date fair value and is recognized on a ratable basis over the requisite service periods of the awards, which are generally the vesting periods. We issue employee share-based awards in the form of stock options and restricted stock units under our equity incentive plans and stock purchase rights under our employee stock purchase plan. Stock Options, Stock Purchase Rights and Restricted Stock Units During the fiscal years ended December 31, 2015, 2014 and 2013, the weighted average fair value per share of the employee stock options, restricted stock units and stock purchase rights granted were: 2015 2014 2013 Stock Options $ 0.80 $ 2.83 $ 3.46 Restricted Stock Units — — 4.67 Stock Purchase Rights 0.67 1.32 1.76 The estimated grant date fair values of the stock options and stock purchase rights were calculated using the Black-Scholes valuation model. The Black-Scholes model requires the use of a number of highly subjective and complex assumptions in determining the fair value of stock-based awards as follows: Weighted-Average Expected Term We determine the expected term of stock options granted through a combination of our own historical exercise experience and expected future exercise activities and post-vesting termination behavior. Under our 2005 Employee Stock Purchase Plan and our 2015 Employee Stock Purchase Plan, the expected term of employee stock purchase plan shares is equal to the offering period. Volatility We utilize our historical volatility to determine future volatility for the purpose of determining share-based payments for all options granted. Risk-Free Interest Rate We utilize U.S. Treasury zero-coupon issues with remaining terms similar to the expected term of the options or purchase rights on the respective grant dates to determine our risk-free interest rate. Dividend Yield We have never declared or paid any cash dividends and do not plan to pay cash dividends in the foreseeable future, and, therefore, use an expected dividend yield of zero in the valuation model. Forfeiture Rate We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. All stock-based payment awards are amortized on a straight-line basis over the requisite service periods of the awards, which are generally the vesting periods. During the fiscal years ended December 31, 2015, 2014 and 2013, we calculated the estimated grant date fair value of stock options and stock purchase rights using the following assumptions: 2015 2014 2013 Stock Option Plans Weighted-average expected term 5.0 Years 5.0 Years 5.0 Years Expected volatility 86% 83% 99% Risk-free interest rate 1.60% 1.66% 0.86% Dividend yield 0% 0% 0% Employee Stock Purchase Plan Weighted-average expected term 0.5 Years 0.5 Years 0.5 Years Expected volatility 87% 61% 80% Risk-free interest rate 0.19% 0.86% 0.70% Dividend yield 0% 0% 0% Restricted Stock Units The estimated fair value of restricted stock unit awards is calculated based on the market price of our common stock on the date of grant, reduced by the present value of dividends expected to be paid on our common stock prior to vesting of the restricted stock unit. Our estimate assumes no dividends will be paid prior to the vesting of the restricted stock unit. In 2013, certain restricted stock unit awards were issued that vest based on market conditions. The estimated fair value of these awards was calculated using a binomial lattice model with a term of 10 years, an expected volatility of 99.4%, a risk-free interest rate of 1.94% and a dividend yield of 0%. As of December 31, 2015, there were $1,725,000, $94,000 and $3,000 total unrecognized compensation costs, net of forfeiture, related to non-vested stock option awards, restricted stock unit awards and stock purchase rights, respectively, which are expected to be recognized over a weighted average period of 3.0 years, 1.1 years and 0.05 years, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under the current guidance. ASU 2014-15 is effective for us in the first quarter of 2016 with early adoption permitted. In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), that will supersede nearly all existing revenue recognition guidance under US GAAP. The core principle of the guidance is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. The standard will be effective for public entities for annual and interim periods beginning after December 15, 2017. Entities can choose to apply the standard using either the full retrospective approach or a modified retrospective approach. Entities electing the full retrospective adoption will apply the standard to each period presented in the financial statements. This means that entities will have to apply the new guidance as if it had been in effect since the inception of all its contracts with customers presented in the financial statements. Entities that elect the modified retrospective approach will apply the guidance retrospectively only to the most current period presented in the financial statements. This means that entities will have to recognize the cumulative effect of initially applying the new standard as an adjustment to the opening balance of retained earnings at the date of initial application. The new revenue standard will be applied to contracts that are in progress at the date of initial application. In July 2015, the Financial Accounting Standards Board issued ASU No. 2015-14, which delays the effective date of the standard for one year to annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. We are evaluating the requirements of this guidance and have not yet determined the impact of its adoption on our consolidated financial position, results of operations and cash flows. In April 2015, the Financial Accounting Standards Board issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In February 2016, the Financial Accounting Standards Board issued ASU 2016-02, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) -
Operating Leases	We recognize rental expense on the 2091 Building on a straight line basis over the initial term of the lease. Differences between the straight line rent expense and actual rent payments are classified as deferred rent liability on the balance sheet.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Financial Assets by Major Security Type and Contingent Consideration Liability Measured at Fair Value on Recurring Basis	The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) by major security type and contingent consideration liability measured at fair value on a recurring basis as of December 31, 2015 and 2014 (in thousands): December 31, 2015 Level 1 Level 2 Level 3 Total Assets Money market funds $ 6,806 $ — $ — $ 6,806 Corporate debt securities — — — — Total assets $ 6,806 $ — $ — $ 6,806 Liabilities Contingent consideration liability $ — $ — $ 2,800 $ 2,800 Total liabilities $ — $ — $ 2,800 $ 2,800 December 31, 2014 Level 1 Level 2 Level 3 Total Assets Money market funds $ 12,674 $ — $ — $ 12,674 Corporate debt securities — 24,617 — 24,617 Total assets $ 12,674 $ 24,617 $ — $ 37,291 Liabilities Contingent consideration liability $ — $ — $ 30,800 $ 30,800 Total liabilities $ — $ — $ 30,800 $ 30,800
Fair Value Measurement of Contingent Consideration Liability	The following table represents a reconciliation of the change in the fair value measurement of the contingent consideration liability for the fiscal years ended December 31, 2015 and 2014 (in thousands): December 31, 2015 2014 (In thousands) Beginning balance $ 30,800 $ 39,200 Payments made (868 ) (251 ) Adjustments to fair value measurement (27,132 ) (8,149 ) Ending balance $ 2,800 $ 30,800
Schedule of Inventory	Our inventory as of December 31, 2015 and 2014, net of reserves, in thousands, is summarized as follows: December 31, 2015 2014 Raw materials $ — $ 3,677 Work in process — — Finished goods — 52 Total inventory $ — $ 3,729
Share-based Compensation Grant Date Fair Value	During the fiscal years ended December 31, 2015, 2014 and 2013, the weighted average fair value per share of the employee stock options, restricted stock units and stock purchase rights granted were: 2015 2014 2013 Stock Options $ 0.80 $ 2.83 $ 3.46 Restricted Stock Units — — 4.67 Stock Purchase Rights 0.67 1.32 1.76
Share-based Compensation Assumptions	During the fiscal years ended December 31, 2015, 2014 and 2013, we calculated the estimated grant date fair value of stock options and stock purchase rights using the following assumptions: 2015 2014 2013 Stock Option Plans Weighted-average expected term 5.0 Years 5.0 Years 5.0 Years Expected volatility 86% 83% 99% Risk-free interest rate 1.60% 1.66% 0.86% Dividend yield 0% 0% 0% Employee Stock Purchase Plan Weighted-average expected term 0.5 Years 0.5 Years 0.5 Years Expected volatility 87% 61% 80% Risk-free interest rate 0.19% 0.86% 0.70% Dividend yield 0% 0% 0%

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Potentially Anti-Dilutive Securities	Potentially anti-dilutive securities include the following (in thousands): Year Ended December 31, 2015 2014 2013 Outstanding stock options 2,130 2,429 1,657 Unvested restricted stock units 58 371 315 Warrants to purchase common stock 5,763 6,561 6,462 Convertible debt 5,499 4,803 651

Cash Equivalents and Marketab26

Cash Equivalents and Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2015
Cash And Cash Equivalents [Abstract]
Schedule of Cash Equivalents and Marketable Securities	The amortized cost, fair value and unrealized gain/(loss) for our financial assets by major security type as of December 31, 2015 and 2014 are as follows (in thousands): Amortized Unrealized December 31, 2015 Cost Fair Value Gain/(Loss) Money market funds $ 6,806 $ 6,806 $ — Corporate debt securities — — — Total 6,806 6,806 — Less amounts classified as cash equivalents (6,806 ) (6,806 ) — Total marketable securities $ — $ — $ — Amortized Unrealized December 31, 2014 Cost Fair Value Gain/(Loss) Money market funds $ 12,674 $ 12,674 $ — Corporate debt securities 24,620 24,617 (3 ) Total 37,294 37,291 (3 ) Less amounts classified as cash equivalents (17,717 ) (17,717 ) — Total marketable securities $ 19,577 $ 19,574 $ (3 )

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Components of Property and Equipment	Property and equipment consisted of the following (in thousands): December 31, 2015 2014 (In thousands) Lab equipment $ 1,369 $ 9,850 Manufacturing equipment — 11,239 Computer equipment and software 4,839 5,136 Furniture 774 816 Leasehold improvements 18,950 18,950 Property and equipment, gross 25,932 45,991 Less: accumulated depreciation (22,612 ) (32,038 ) Property and equipment, net $ 3,320 $ 13,953
Components of Other Accrued Liabilities	Other accrued liabilities consisted of the following (in thousands): December 31, 2015 2014 (In thousands) Accrued interest $ 3,032 $ — Accrued compensation 2,035 2,781 Accrued capital project payment 916 — Accrued professional fees 569 1,144 Other 438 768 $ 6,990 $ 4,693

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Future Minimum Lease Payments by Year	Future minimum lease payments under non-cancelable operating leases, at December 31, 2015 were as follows (in thousands): Lease Payments 2016 $ 3,305 2017 3,386 2018 853 2019 — 2020 — Thereafter — Total minimum payments $ 7,544

Financing Obligations (Tables)

Financing Obligations (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Effective Interest Rate Drawdown after Taking into Consideration Beneficial Ownership Features and Right to Borrow Asset Discount	The following table shows the effective interest rate for each drawdown after taking into consideration the beneficial ownership features and the right-to-borrow asset discount. Reclassified Beneficial Unamortized Effective Draw Conversion Right-to- Interest Amount Feature Borrow Rate September 2013 $ 10,000,000 $ 2,455,000 $ 900,000 14.20 % December 2013 5,000,000 657,000 393,000 10.20 % March 2014 5,000,000 883,000 318,000 11.60 % June 2014 5,000,000 148,000 252,000 6.60 %
Long Term Debt Payments by Year	Future scheduled principal payments under the debt obligations as of December 31, 2015 are as follows (in thousands): Total 2016 $ 3,000 2017 — 2018 — 2019 — Thereafter 25,000 Total $ 28,000

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Option Activity under Company's Share-Based Compensation Plans	The following table sets forth the summary of option activity under our share-based compensation plans: Outstanding Options Number of Weighted Shares Exercise Price Balance as of January 1, 2015 1,978,273 $ 7.10 Options granted 1,544,300 1.19 Options exercised — — Options forfeited — — Options cancelled (1,196,172 ) 5.04 Balance as of December 31, 2015 2,326,401 4.23
Information Regarding Stock Options Outstanding	Information regarding the stock options outstanding at December 31, 2015 is summarized as follows: Outstanding Exercisable Remaining Remaining Contractual Aggregate Contractual Aggregate Number Life Intrinsic Number Life Intrinsic Exercise Price of Shares (In Years) Value of Shares (In Years) Value $0.88 - $0.88 18,000 9.97 $ — — — $ — $1.08 - $1.08 1,017,706 9.48 — 112,902 8.91 — $1.20 - $1.95 238,100 9.52 — 450 8.92 — $1.97 - $3.50 239,247 6.23 — 172,729 5.55 — $4.14 - $4.42 239,751 6.12 — 233,227 6.08 — $4.48 - $4.68 290,341 7.34 — 132,142 6.22 — $4.77 - $21.00 237,349 4.73 — 215,428 4.43 — $23.70 - $90.10 43,293 2.45 — 43,293 2.45 — $98.50 - $98.50 2,500 1.39 2,500 1.39 $117.00 - $117.00 114 1.01 — 114 1.01 — 2,326,401 7.92 $ — 912,785 5.78 $ —
Summary of Unvested Share Units (Restricted Stock Units)	Information with respect to unvested share units (restricted stock units) as of December 31, 2015 is as follows: Weighted Number Average of Grant Date Shares Fair Value Outstanding at January 1, 2015 81,050 $ 4.67 Granted — — Released (21,875 ) 4.67 Forfeited (22,225 ) 4.67 Outstanding at December 31, 2015 36,950 4.67
2005 Plan and the Directors’ Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Authorized Shares of Common Stock for Issuance	We authorized shares of common stock for issuance under the 2005 Plan and the Directors’ Plan as follows. Year Number of Shares 2013 2,319,812 2014 158,751 2015 175,000
2015 Plan and the 2015 Directors’ Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Authorized Shares of Common Stock for Issuance	We authorized shares of common stock for issuance under the 2015 Plan and the 2015 Directors’ Plan as follows. Year Number of Shares 2015 1,250,000

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Summarized Report of Domestic Federal Statutory Tax Rates to Loss before Income Taxes from Operations	The reported amount of income tax expense (benefit) attributable to operations for the year differs from the amount that would result from applying domestic federal statutory tax rates to loss before income taxes from operations as summarized below (in thousands): Year Ended December 31, 2015 2014 2013 Federal tax benefit at statutory rate $ (7,246 ) $ (12,489 ) $ (13,469 ) State tax benefit net of federal effect (1,243 ) (2,143 ) (2,311 ) Research and development credits (456 ) (560 ) (532 ) Other permanent differences 8 2 14 Share-based compensation 678 414 650 Adjustment to basis in subsidiary (10,808 ) (3,246 ) 15,899 Change in valuation allowance 17,140 16,946 (357 ) Reduction of deferred tax asset attributed to expired net operating loss carryforward 1,927 1,076 106 Other — — — Total $ — $ — $ —
Report of Company's Deferred Tax Assets	Significant components of our deferred tax assets are as follows (in thousands): December 31, 2015 2014 Federal and state net operating loss carryforwards $ 139,874 $ 130,011 Federal and state research and development credit carryforwards 16,222 15,536 Accrued liabilities 3,460 7,177 Properties and Equipment 7,740 — Capitalized research and development costs 16,263 16,027 Other 1,842 2,092 Total deferred tax assets 185,401 170,843 Valuation allowance (185,401 ) (170,843 ) Net deferred tax assets $ — $ —
Reconciliation Report of Beginning and Ending Amount of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Balance at January 1, 2013 $ 3,014 Additions based on tax positions taken during a prior period — Reductions based on tax positions taken during a prior period (231 ) Additions based on tax positions taken during the current period 36 Reductions based on tax positions taken during the current period — Reductions related to settlement of tax matters — Reductions related to a lapse of applicable statute of limitations — Balance at December 31, 2013 2,819 Additions based on tax positions taken during a prior period — Reductions based on tax positions taken during a prior period — Additions based on tax positions taken during the current period 113 Reductions based on tax positions taken during the current period — Reductions related to settlement of tax matters — Reductions related to a lapse of applicable statute of limitations — Balance at December 31, 2014 2,932 Additions based on tax positions taken during a prior period 87 Reductions based on tax positions taken during a prior period — Additions based on tax positions taken during the current period 95 Reductions based on tax positions taken during the current period — Reductions related to settlement of tax matters — Reductions related to a lapse of applicable statute of limitations — Balance at December 31, 2015 $ 3,114

Quarterly Results (Tables)

Quarterly Results (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Results	The following table is in thousands, except per share amounts: Quarter Ended March 31 June 30 September 30 December 31 Fiscal 2015 Revenues $ 705 $ 1,875 $ 1,773 $ 673 Loss from operations (13,003 ) (9,441 ) (7,597 ) (9,983 ) Net loss (404 ) (12,450 ) (5,438 ) (3,018 ) Basic and diluted net loss per share (0.02 ) (0.63 ) (0.27 ) (0.15 ) Fiscal 2014 Revenues $ 2,166 $ 1,484 $ 457 $ 1,454 Loss from operations (8,803 ) (11,349 ) (10,040 ) (7,264 ) Net loss (10,735 ) (5,962 ) (13,328 ) (6,707 ) Basic and diluted net loss per share (0.62 ) (0.34 ) (0.77 ) (0.35 )

Financing Obligations - Additio

Financing Obligations - Additional Information (Detail) - USD ($)	Mar. 21, 2016	Sep. 28, 2015	Mar. 23, 2016	Feb. 29, 2016	Mar. 31, 2014	Feb. 28, 2011	Jun. 30, 2010	Dec. 31, 2015	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2015	May. 31, 2013
Debt Instrument [Line Items]
Common stock shares issued								19,577,729					19,577,729	19,404,697
Proceeds from financing obligations													$ 2,914,000	$ 50,830,000	$ 15,000,000
Aggregate annual net sales of ADASUVE and Staccato enabled products													2,355,000	2,564,000	874,000
Non-recourse notes issued					$ 45,000,000								$ 45,000,000
Warrants to purchase common stock					345,661			345,661		345,661			345,661
Price of common stock per share					$ 0.01					$ 0.01
Warrant exercisable term					5 years
First quarterly interest payment													Jun. 15, 2014
Interest reserve					$ 6,890,000					$ 6,890,000				2,757,000
Expected volatility rate					87.00%
Estimated life of the warrant					5 years								5 years
Risk-free interest rate					1.54%
Expected dividend yield					0.00%
Value of warrants issued with royalty securitization financing					$ 1,721,000					1,721,000				1,721,000
Interest expense amortization period					5 years			5 years					5 years
Total fees and expenses					$ 4,171,000
Payment of interest in debt instrument								$ 0
Default interest payable								$ 2,800,000					$ 2,800,000
Renewal period								30 days
Amortization of debt discount								$ 74,000
Common stock value of shares issued								2,000					2,000	2,000
Financing from royalty securitization								$ 45,000,000					$ 45,000,000
Royalty securitization financing legal maturity date													2,027
Ferrer Note [Member]
Debt Instrument [Line Items]
Promissory note, due date		May 31, 2016
Debt instrument interest rate		6.00%
Common stock shares issued		125,000
Proceeds from financing obligations		$ 3,000,000
Additional tranche to borrow																$ 1,000,000
Debt instrument, effective interest rate		10.50%
Percentage of common stock issued recorded as discount to promissory notes		60.00%
Percentage of common stock issued capitalized		40.00%
Common stock value of shares issued		$ 144,000
Ferrer Note [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Proceeds from financing obligations	$ 1,000,000		$ 1,000,000
Principal amount of the Ferrer Note outstanding			$ 4,000,000
Ferrer Note [Member] | Maximum [Member]
Debt Instrument [Line Items]
Principal amount of promissory note																$ 5,000,000
Ferrer Promissory Note Tranche Two [Member]
Debt Instrument [Line Items]
Promissory note, due date		May 31, 2016
Ferrer Promissory Note Tranche Two [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Proceeds from financing obligations	$ 1,000,000
Autoliv ASP, Inc. [Member]
Debt Instrument [Line Items]
Amount of cash paid to Autoliv ASP, Inc.							$ 4,000,000
Value of cancelled note						$ 4,000,000
Autoliv ASP, Inc. [Member] | Original Note [Member]
Debt Instrument [Line Items]
Value of unsecured promissory note issued							$ 4,000,000
Autoliv ASP, Inc. [Member] | New Note [Member]
Debt Instrument [Line Items]
Debt instrument interest rate						8.00%
Value of unsecured promissory note issued						$ 2,800,000
Installment period of New Note						48 months
Periodic payment of New Note						$ 68,000
Teva Pharmaceuticals USA, Inc. [Member]
Debt Instrument [Line Items]
Debt instrument interest rate																	400.00%
Proceeds from financing obligations									$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 10,000,000		25,000,000
Debt instrument payment terms													At any time prior to five days before the maturity date, Teva has the right to convert the then outstanding amounts into shares of our common stock at a conversion price of $4.4833 per share.
Debt instrument conversion price per share																	$ 4.4833
Interest expense under right-to-borrow asset														$ 216,000	$ 752,000
Debt instrument, effective interest rate					11.60%				6.60%	11.60%	10.20%	14.20%			10.20%
Teva Note [Member]
Debt Instrument [Line Items]
Debt instrument, effective interest rate					12.25%					12.25%
Notes redemption description													The Notes have no other recourse to us. The Notes may not be redeemed at our option until after March 18, 2016, and may be redeemed after that date subject to the achievement of certain milestones and the payment of a redemption premium for any redemption occurring prior to March 19, 2019.
Teva Note [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Periodic payment of New Note				$ 5,000,000
Common stock issued for reduction in outstanding balance of Notes				2,172,886
Reduction in outstanding balance of Notes				$ 5,000,000
Outstanding balance of Notes				$ 20,000,000
Frequency of periodic payment				Four
Aggregate annual net sales of ADASUVE and Staccato enabled products				$ 50,000,000

The Company - Additional Inform

The Company - Additional Information (Detail)

Mar. 21, 2016USD ($)

Sep. 28, 2015USD ($)shares

Oct. 27, 2014USD ($)$ / sharesshares

Feb. 23, 2012USD ($)$ / sharesshares

Oct. 31, 2009$ / sharesshares

Mar. 23, 2016USD ($)

Oct. 31, 2014shares

Mar. 31, 2014$ / sharesshares

Dec. 31, 2015USD ($)Segmentshares

Dec. 31, 2014USD ($)shares

Dec. 31, 2013USD ($)shares

Sep. 30, 2015USD ($)

Product Information [Line Items]

Business incorporation, state country name

State of Delaware

Business incorporation, date

Dec. 19, 2000

Number of business segment | Segment

1

Common stock shares issued | shares

19,577,729

19,404,697

Number of common shares, callable by warrants issued in the aggregate stock and warrants sale | shares

345,661

345,661

Exercise price of warrant | $ / shares

$ 0.01

Warrant expiration date

May 31, 2019

Proceeds from financing obligations | $

$ 2,914,000

$ 50,830,000

$ 15,000,000

Common Stock [Member]

Product Information [Line Items]

Common stock shares issued during the period | shares

125,000

2,000,000

1,437,481

Ferrer Note [Member]

Product Information [Line Items]

Common stock shares issued | shares

125,000

Proceeds from financing obligations | $

$ 3,000,000

Additional tranche to borrow | $

$ 1,000,000

Debt instrument interest rate

6.00%

Promissory note, due date

May 31, 2016

Ferrer Note [Member] | Common Stock [Member]

Product Information [Line Items]

Common stock shares issued during the period | shares

125,000

Ferrer Note [Member] | Maximum [Member]

Product Information [Line Items]

Principal amount of promissory note | $

$ 5,000,000

Ferrer Note [Member] | Subsequent Event [Member]

Product Information [Line Items]

Proceeds from financing obligations | $

$ 1,000,000

$ 1,000,000

Principal amount of the Ferrer Note outstanding | $

$ 4,000,000

Ferrer Promissory Note Initial Tranche [Member]

Product Information [Line Items]

Proceeds from promissory note | $

$ 3,000,000

Ferrer Promissory Note Tranche Two [Member]

Product Information [Line Items]

Promissory note, due date

May 31, 2016

Ferrer Promissory Note Tranche Two [Member] | Subsequent Event [Member]

Product Information [Line Items]

Proceeds from financing obligations | $

$ 1,000,000

Grupo Ferrer Internacional, S.A. [Member]

Product Information [Line Items]

Common stock shares issued during the period | shares

2,000,000

Underwritten Public Offering [Member]

Product Information [Line Items]

Common stock shares issued | shares

4,400,000

Number of common shares, callable by warrants issued in the aggregate stock and warrants sale | shares

4,400,000

Net proceeds received in the aggregate stock and warrants sale | $

$ 20,231,000

Exercise price of warrant | $ / shares

$ 5

Warrant expiration date

Feb. 23, 2017

Date from which warrants are exercisable

Feb. 24, 2013

Private Placement [Member]

Product Information [Line Items]

Common stock shares issued | shares

8,107,012

Number of common shares, callable by warrants issued in the aggregate stock and warrants sale | shares

7,296,312

Exercise price of warrant | $ / shares

$ 2.77

Warrant expiration date

Oct. 31, 2016

Private Placement [Member] | Grupo Ferrer Internacional, S.A. [Member]

Product Information [Line Items]

Amount of consideration received by company in exchange for shares sold in transaction | $

$ 8,000,000

Sale of stock, number of shares issued in transaction | shares

2,000,000

Common stock average price per share | $ / shares

$ 4

Premium on the fair value from sale of stock, classified as deferred revenue | $

$ 2,400,000

Need to Raise Additional Capi35

Need to Raise Additional Capital - Additional Information (Detail)	Mar. 21, 2016USD ($)	Feb. 29, 2016USD ($)Installmentshares	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Jan. 01, 2013USD ($)
Need To Raise Additional Capital [Line Items]
Cash and cash equivalents			$ 7,755,000	$ 15,200,000	$ 17,306,000	$ 17,715,000
Working capital deficiency			$ (47,206,000)
Operating and capital plans			12 months
Proceeds from financing obligations			$ 2,914,000	$ 50,830,000	$ 15,000,000
Subsequent Event [Member] | Ferrer Promissory Note Tranche Two [Member]
Need To Raise Additional Capital [Line Items]
Proceeds from financing obligations	$ 1,000,000
Subsequent Event [Member] | Teva Note [Member]
Need To Raise Additional Capital [Line Items]
Common stock shares issued upon debt conversion | shares		2,172,886
Reduction in outstanding balance of Notes		$ 5,000,000
Outstanding balance of notes		$ 20,000,000
Number of annual consecutive payments | Installment		4
Annual consecutive payments amount		$ 5,000,000
Aggregate annual net sales of ADASUVE and Staccato enabled products		$ 50,000,000
Subsequent Event [Member] | Teva Note [Member] | Common Stock [Member]
Need To Raise Additional Capital [Line Items]
Common stock shares issued upon debt conversion | shares		2,172,886

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Financial Assets by Major Security Type and Contingent Consideration Liability Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Assets
Cash and cash equivalents, fair value disclosure	$ 6,806	$ 17,717
Total assets	6,806	37,291
Liabilities
Contingent consideration liability	2,800	30,800
Total liabilities	2,800	30,800
Money Market Funds [Member]
Assets
Cash and cash equivalents, fair value disclosure	6,806	12,674
Corporate Debt Securities [Member]
Assets
Cash and cash equivalents, fair value disclosure	0	24,617
Level 1 [Member]
Assets
Total assets	6,806	12,674
Liabilities
Contingent consideration liability	0	0
Total liabilities	0	0
Level 1 [Member] | Money Market Funds [Member]
Assets
Cash and cash equivalents, fair value disclosure	6,806	12,674
Level 1 [Member] | Corporate Debt Securities [Member]
Assets
Cash and cash equivalents, fair value disclosure	0	0
Level 2 [Member]
Assets
Total assets	0	24,617
Liabilities
Contingent consideration liability	0	0
Total liabilities	0	0
Level 2 [Member] | Money Market Funds [Member]
Assets
Cash and cash equivalents, fair value disclosure	0	0
Level 2 [Member] | Corporate Debt Securities [Member]
Assets
Cash and cash equivalents, fair value disclosure	0	24,617
Level 3 [Member]
Assets
Total assets	0	0
Liabilities
Contingent consideration liability	2,800	30,800
Total liabilities	2,800	30,800
Level 3 [Member] | Money Market Funds [Member]
Assets
Cash and cash equivalents, fair value disclosure	0	0
Level 3 [Member] | Corporate Debt Securities [Member]
Assets
Cash and cash equivalents, fair value disclosure	$ 0	$ 0

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
Business Acquisition, Contingent Consideration [Line Items]
Increased (decreased) in net loss resulted from change in discount rate			$ 6,400,000	$ 3,600,000
Increased (decreased) in net loss per share resulted from change in discount rate			$ 0.36	$ 0.22
Increase / decrease in contingent consideration liability and non-operating, non-cash gain (loss)		$ 27,132,000	$ (8,149,000)
Increase (decrease) in net loss per share		$ 1.37	$ (0.46)
Estimated fair value of financing obligations		$ 52,151,000	$ 52,075,000
Book values of financing obligations		$ 67,967,000	63,767,000
Maturity period of highly liquid investments		Three months or less
Interest reserve			2,757,000		$ 6,890,000
Impairment of property and equipment		$ 8,591,000	0
Additional cost of goods sold related to inventory		1,229,000
Prepayments to supplier for lower housing assembly		$ 1,024,000
Inventory impairment charges			$ 0
Uncertain tax position recognition likelihood percentage		50.00%
Allegro stockholders [Member]
Business Acquisition, Contingent Consideration [Line Items]
Payments To Former Allegro Stockholders	$ 900,000
Maximum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Cash flow discount rate			20.00%	18.00%
Minimum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Cash flow discount rate			16.50%	16.50%

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Fair Value Measurement of Contingent Consideration Liability (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Beginning balance	$ 30,800	$ 39,200
Payments made	(868)	(251)
Adjustments to fair value measurement	(27,132)	(8,149)
Ending balance	$ 2,800	$ 30,800

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Useful Life - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated life of the asset	3 years
Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated life of the asset	5 years
Furniture [Member]
Property, Plant and Equipment [Line Items]
Estimated life of the asset	7 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements description	Leasehold improvements are amortized over the estimated useful life or the remaining lease term, whichever is shorter.

Summary of Significant Accoun40

Summary of Significant Accounting Policies - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 0	$ 3,677
Work in process	0	0
Finished goods	0	52
Total inventory	$ 0	$ 3,729

Summary of Significant Accoun41

Summary of Significant Accounting Policies - Share-based Compensation Grant Date Fair Value (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options	$ 0.80	$ 2.83	$ 3.46
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted Stock Units or Stock Purchase Rights	0	0	4.67
Stock Purchase Rights [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted Stock Units or Stock Purchase Rights	$ 0.67	$ 1.32	$ 1.76

Summary of Significant Accoun42

Summary of Significant Accounting Policies - Share-based Compensation Assumptions (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average expected term	5 years	5 years	5 years
Expected volatility	86.00%	83.00%	99.00%
Risk-free interest rate	1.60%	1.66%	0.86%
Dividend yield	0.00%	0.00%	0.00%
Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average expected term	6 months	6 months	6 months
Expected volatility	87.00%	61.00%	80.00%
Risk-free interest rate	0.19%	0.86%	0.70%
Dividend yield	0.00%	0.00%	0.00%

Summary of Significant Accoun43

Summary of Significant Accounting Policies - Share-based Compensation by Award Type - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2005
Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 months	6 months	6 months
Expected volatility	87.00%	61.00%	80.00%
Risk-free interest rate	0.19%	0.86%	0.70%
Dividend yield	0.00%	0.00%	0.00%
Unrecognized compensation costs related to non-vested stock option awards	$ 1,725,000
Costs expected to be recognized over a weighted average period				3 years
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term			10 years
Expected volatility			99.40%
Risk-free interest rate			1.94%
Dividend yield			0.00%
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	5 years	5 years	5 years
Expected volatility	86.00%	83.00%	99.00%
Risk-free interest rate	1.60%	1.66%	0.86%
Dividend yield	0.00%	0.00%	0.00%
Unrecognized compensation costs	$ 94,000
Costs expected to be recognized over a weighted average period				1 year 1 month 6 days
Restricted stock unit awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation costs	$ 3,000
Costs expected to be recognized over a weighted average period				6 months

Net Loss per Share - Additional

Net Loss per Share - Additional information (Detail) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Weighted average shares subject to repurchase	0	0	0

Net Loss per Share - Potentiall

Net Loss per Share - Potentially Anti-Dilutive Securities (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	2,130	2,429	1,657
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	58	371	315
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	5,763	6,561	6,462
Convertible debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	5,499	4,803	651

Cash Equivalents and Marketab46

Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Cash Cash Equivalents And Investments [Line Items]
Amortized Cost	$ 0	$ 19,577
Fair Value	0	19,574
Unrealized Gain/(Loss)	0	(3)
Less amounts classified as cash equivalents, Amortized Cost	(6,806)	(17,717)
Less amounts classified as cash equivalents, Fair Value	(6,806)	(17,717)
Less amounts classified as cash equivalents, Unrealized Gain/(Loss)	0	0
Money Market Funds [Member]
Cash Cash Equivalents And Investments [Line Items]
Amortized Cost	6,806	12,674
Fair Value	6,806	12,674
Unrealized Gain/(Loss)	0	0
Less amounts classified as cash equivalents, Fair Value	(6,806)	(12,674)
Corporate Debt Securities [Member]
Cash Cash Equivalents And Investments [Line Items]
Amortized Cost	0	24,620
Fair Value	0	24,617
Unrealized Gain/(Loss)	0	(3)
Less amounts classified as cash equivalents, Fair Value	0	(24,617)
Total [Member]
Cash Cash Equivalents And Investments [Line Items]
Amortized Cost	6,806	37,294
Fair Value	6,806	37,291
Unrealized Gain/(Loss)	$ 0	$ (3)

Balance Sheet Components - Comp

Balance Sheet Components - Components of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 25,932	$ 45,991
Less: accumulated depreciation	(22,612)	(32,038)
Property and equipment, net	3,320	13,953
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,369	9,850
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		11,239
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,839	5,136
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	774	816
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 18,950	$ 18,950

Balance Sheet Components - Co48

Balance Sheet Components - Components of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Payables And Accruals [Abstract]
Accrued interest	$ 3,032
Accrued compensation	2,035	$ 2,781
Accrued capital project payment	916
Accrued professional fees	569	1,144
Other	438	768
Total other accrued liabilities	$ 6,990	$ 4,693

Commitments and Contingencies -

Commitments and Contingencies - Operating Leases - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)Option	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Operating Leased Assets [Line Items]
Rent expenses, net of sublease income	$ 1,828,000	$ 1,953,000	$ 2,286,000
Rental income from the sublease agreement	$ 0	$ 0	$ 0
2091 Building [Member]
Operating Leased Assets [Line Items]
Expiry of lease of 2091 Building	Mar. 31, 2018
Operating leases renewal term, duration	5 years
Operating leases options | Option	2

Commitments and Contingencies50

Commitments and Contingencies - Future Minimum Lease Payments by Year (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,016	$ 3,305
2,017	3,386
2,018	853
2,019	0
2,020	0
Thereafter	0
Total minimum payments	$ 7,544

Commitments and Contingencies51

Commitments and Contingencies - Manufacturing and Supply - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Agreement termination year	2,018
Additional manufacturing cell cost	$ 2,350,000
Impairment of property and equipment	8,591,000	$ 0
Additional cost of goods sold related to inventory	1,229,000
Prepayments to supplier for lower housing assembly	$ 1,024,000

Commitments and Contingencies52

Commitments and Contingencies - Contingencies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)
Commitments And Contingencies Disclosure [Abstract]
Provisions for liabilities	$ 0

Financing Obligations - Schedul

Financing Obligations - Schedule of Effective Interest Rate Drawdown after Taking into Consideration Beneficial Ownership Features and Right to Borrow Asset Discount (Detail) - USD ($)	3 Months Ended				12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Draw Amount					$ 2,914,000	$ 50,830,000	$ 15,000,000
Beneficial Conversion Feature			$ 3,112,000			1,032,000	3,112,000
Teva Pharmaceuticals USA, Inc. [Member]
Debt Instrument [Line Items]
Draw Amount	$ 5,000,000	$ 5,000,000	5,000,000	$ 10,000,000		$ 25,000,000
Beneficial Conversion Feature	148,000	883,000	657,000	2,455,000			657,000
Reclassified Unamortized Right-to-Borrow	$ 252,000	$ 318,000	$ 393,000	$ 900,000			$ 393,000
Debt instrument, effective interest rate	6.60%	11.60%	10.20%	14.20%			10.20%

Financing Obligations - Long Te

Financing Obligations - Long Term Debt Payments by Year (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Debt Disclosure [Abstract]
2,016	$ 3,000
2,017	0
2,018	0
2,019	0
Thereafter	25,000
Total	$ 28,000

License Agreements - Additional

License Agreements - Additional Information (Detail) - USD ($)	Oct. 05, 2011	Jan. 31, 2015	Oct. 31, 2014	Jan. 31, 2014	Mar. 31, 2012	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue						$ 2,671,000	$ 2,997,000	$ 46,965,000
Teva Pharmaceuticals USA, Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront cash received under collaborative arrangement								40,000,000
Grupo Ferrer Internacional, S.A. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront cash received under collaborative arrangement	$ 10,000,000
Eligible receipt of additional milestone payments	51,000,000					$ 40,000,000
License agreement contractual terms						until the later of the last to expire patent covering ADASUVE in such country or 12 years after first commercial sale.
License agreement term period						12 years
Issuance of common stock for cash, shares			2,000,000
Common stock price, per share			$ 4
Purchase of common stock, value			$ 8,000,000
Estimated performance period of agreement						4 years
Upfront cash received under collaborative arrangement				$ 1,000,000
Collaboration revenue						$ 2,666,000	$ 1,987,000	$ 2,915,000
Deferred revenue						$ 2,848,000
Grupo Ferrer Internacional, S.A. [Member] | Upfront payment [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Premium on the fair value from sale of stock, classified as deferred revenue			$ 2,400,000		$ 1,452,000
Grupo Ferrer Internacional, S.A. [Member] | Symphony Allegro Incorporation [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments To Former Allegro Stockholders		$ 865,000
Symphony Allegro Incorporation [Member] | Grupo Ferrer Internacional, S.A. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to former stockholders under collaborative arrangement	$ 5,000,000			$ 250,000

Warrants - Additional Informati

Warrants - Additional Information (Detail)	Feb. 23, 2012$ / sharesshares	May. 06, 2011$ / sharesshares	Aug. 10, 2010$ / shares$ / Stockshares	Oct. 31, 2009$ / shares$ / Stockshares	Mar. 31, 2014$ / sharesshares	May. 31, 2010$ / sharesshares	Dec. 31, 2015shares	Dec. 31, 2014shares
Class of Warrant or Right [Line Items]
Common stock shares issued							19,577,729	19,404,697
Number of common shares, callable by warrants issued in the aggregate stock and warrants sale					345,661		345,661
Exercise price of warrant | $ / shares					$ 0.01
Warrant expiration date					May 31, 2019
Common stock, shares outstanding							19,577,729	19,404,697
Contractual term of the warrant					5 years
Hercules Technology Growth Capital, Inc. [Member]
Class of Warrant or Right [Line Items]
Number of common shares, callable by warrants issued in the aggregate stock and warrants sale						37,639
Exercise price of warrant | $ / shares						$ 26.90
Warrant expiration date						May 31, 2015
Contractual term of the warrant						5 years
Private Placement [Member]
Class of Warrant or Right [Line Items]
Common stock shares issued				8,107,012
Number of common shares, callable by warrants issued in the aggregate stock and warrants sale				7,296,312
Securities sold as units, description of each unit composition							Each unit consisting of one share of common stock and a warrant to purchase 0.9 shares of common stock
Number of common shares, callable by each warrants issued in the aggregate stock and warrants sale				0.9
Securities sold as units, price per unit | $ / Stock				2.4325
Exercise price of warrant | $ / shares				$ 2.77
Warrant expiration date				Oct. 31, 2016
Common stock, shares outstanding				729,627
Registered Direct Equity Issuances [Member]
Class of Warrant or Right [Line Items]
Common stock shares issued		1,192,703	668,518
Number of common shares, callable by warrants issued in the aggregate stock and warrants sale		417,445	334,258
Securities sold as units, description of each unit composition							Each unit consisting of (i) one share of common stock and (ii) a warrant to purchase 0.5 of a share of common stock
Number of common shares, callable by each warrants issued in the aggregate stock and warrants sale			0.5
Securities sold as units, price per unit | $ / Stock			27
Exercise price of warrant | $ / shares		$ 17.55	$ 33
Warrant expiration date		May 31, 2016	Aug. 31, 2015
Underwritten Public Offering [Member]
Class of Warrant or Right [Line Items]
Common stock shares issued	4,400,000
Number of common shares, callable by warrants issued in the aggregate stock and warrants sale	4,400,000
Exercise price of warrant | $ / shares	$ 5
Warrant expiration date	Feb. 23, 2017

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Apr. 30, 2015	May. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2005
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Exercisable			912,785
Options to exercise, shares			1,196,172
2005 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Authorized for issuance thereunder share of common stock						108,879
Effective date of Equity Incentive Plan 2005 and closing date of company's initial public offering						Mar. 8, 2006
Vesting period for stock options and restricted stock units						4 years
Maximum contractual term for issuing new grants stock options and restricted stock units						10 years
Increase in annual reserve by percentage of shares of common stock						2.00%
Increase in annual reserve by shares of common stock						100,000
Shares authorized for issuance include annual reserve					119,812
Shares available for issuance					1,667,850
2005 Equity Incentive Plan [Member] | Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units granted to non-employee directors			1 year
2005 Non-Employee Director's Stock Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Authorized for issuance thereunder share of common stock						25,000
Vesting period for stock options and restricted stock units						4 years
Maximum contractual term for issuing new grants stock options and restricted stock units						10 years
Authorized shares of common stock for issuance, Number of Shares		200,000
Shares authorized for issuance include annual reserve				2,200,000
Shares available for issuance				136,110
2015 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period for stock options and restricted stock units	4 years
Maximum contractual term for issuing new grants stock options and restricted stock units	10 years
Authorized shares of common stock for issuance, Number of Shares	1,000,000
Shares available for issuance			2,503,057
2015 Non Employee Directors' Stock Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period for stock options and restricted stock units	1 year
Maximum contractual term for issuing new grants stock options and restricted stock units	10 years
Authorized shares of common stock for issuance, Number of Shares	250,000
Number of shares, Exercisable			912,785
Weighted average exercise price exercisable			$ 8.16
Intrinsic value of options exercised			$ 0	$ 26,000	$ 13,000
Options to exercise, shares			5,610
Common stock price, per share			$ 0.70
Shares available for issuance			400,000
2011 Employee Stock Option Exchange Program [Member] | Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total value of options exercised restricted stock units			$ 28,000	$ 136,000	$ 75,000
2005 Plan and the Directors’ Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized for issuance include annual reserve			175,000
2015 Plan and the 2015 Directors’ Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Authorized shares of common stock for issuance, Number of Shares			1,250,000
Shares authorized for issuance include annual reserve			1,250,000
2005 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Authorized for issuance thereunder share of common stock						50,000
Increase in annual reserve by percentage of shares of common stock			1.00%
Authorized shares of common stock for issuance, Number of Shares			75,000
Employee stock purchase plan fixed offering period historically						24 months
Employees purchase common stock on their enrollment date			85.00%
Employee stock purchase plan current offering period			6 months
2015 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Authorized shares of common stock for issuance, Number of Shares	500,000
Shares available for issuance			26,157	70,226	54,494
Employees purchase common stock on their enrollment date	85.00%
Shares that were not purchased by our employees			128,249
Shares issued under ESPP			75,000	75,000	75,000
Weighted average price			$ 1.46	$ 2.82	$ 3.67
Shares available for issuance under the ESPP			628,249

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of Option Activity under Company's Share-Based Compensation Plans (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Outstanding at January 1, 2015, Number of Shares | shares	1,978,273
Options granted, Number of Shares | shares	1,544,300
Options exercised, Number of Shares | shares	0
Options forfeited, Number of Shares | shares	0
Options canceled, Number of Shares | shares	(1,196,172)
Outstanding at December 31, 2015, Number of Shares | shares	2,326,401
Outstanding at January 1, 2015, Weighted Average Exercise Price | $ / shares	$ 7.10
Options granted, Weighted Average Exercise Price | $ / shares	1.19
Options exercised, Weighted Average Exercise Price | $ / shares	0
Options forfeited, Weighted Average Exercise Price | $ / shares	0
Options canceled, Weighted Average Exercise Price | $ / shares	5.04
Outstanding at September 30, 2015, Weighted Average Exercise Price | $ / shares	$ 4.23

Equity Incentive Plans - Inform

Equity Incentive Plans - Information Regarding Stock Options Outstanding (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Outstanding	2,326,401	1,978,273
Remaining Contractual Life (In Years), Outstanding	7 years 11 months 1 day
Aggregate Intrinsic Value, Outstanding	$ 0
Number of shares, Exercisable	912,785
Remaining Contractual Life (In Years), Exercisable	5 years 9 months 11 days
Aggregate Intrinsic Value, Exercisable	$ 0
$0.88 - $0.88 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price, Lower Limit	$ 0.88
Exercise Price, Upper Limit	$ 0.88
Number of Shares, Outstanding	18,000
Remaining Contractual Life (In Years), Outstanding	9 years 11 months 19 days
Aggregate Intrinsic Value, Outstanding	$ 0
Aggregate Intrinsic Value, Exercisable	$ 0
$1.08 - $1.08 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price, Lower Limit	$ 1.08
Exercise Price, Upper Limit	$ 1.08
Number of Shares, Outstanding	1,017,706
Remaining Contractual Life (In Years), Outstanding	9 years 5 months 23 days
Aggregate Intrinsic Value, Outstanding	$ 0
Number of shares, Exercisable	112,902
Remaining Contractual Life (In Years), Exercisable	8 years 10 months 28 days
Aggregate Intrinsic Value, Exercisable	$ 0
$1.20 - $1.95 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price, Lower Limit	$ 1.20
Exercise Price, Upper Limit	$ 1.95
Number of Shares, Outstanding	238,100
Remaining Contractual Life (In Years), Outstanding	9 years 6 months 7 days
Aggregate Intrinsic Value, Outstanding	$ 0
Number of shares, Exercisable	450
Remaining Contractual Life (In Years), Exercisable	8 years 11 months 1 day
Aggregate Intrinsic Value, Exercisable	$ 0
$1.97 - $3.50 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price, Lower Limit	$ 1.97
Exercise Price, Upper Limit	$ 3.50
Number of Shares, Outstanding	239,247
Remaining Contractual Life (In Years), Outstanding	6 years 2 months 23 days
Aggregate Intrinsic Value, Outstanding	$ 0
Number of shares, Exercisable	172,729
Remaining Contractual Life (In Years), Exercisable	5 years 6 months 18 days
Aggregate Intrinsic Value, Exercisable	$ 0
$4.14 - $4.42 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price, Lower Limit	$ 4.14
Exercise Price, Upper Limit	$ 4.42
Number of Shares, Outstanding	239,751
Remaining Contractual Life (In Years), Outstanding	6 years 1 month 13 days
Aggregate Intrinsic Value, Outstanding	$ 0
Number of shares, Exercisable	233,227
Remaining Contractual Life (In Years), Exercisable	6 years 29 days
Aggregate Intrinsic Value, Exercisable	$ 0
$4.48 - $4.68 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price, Lower Limit	$ 4.48
Exercise Price, Upper Limit	$ 4.68
Number of Shares, Outstanding	290,341
Remaining Contractual Life (In Years), Outstanding	7 years 4 months 2 days
Aggregate Intrinsic Value, Outstanding	$ 0
Number of shares, Exercisable	132,142
Remaining Contractual Life (In Years), Exercisable	6 years 2 months 19 days
Aggregate Intrinsic Value, Exercisable	$ 0
$4.77 - $21.00 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price, Lower Limit	$ 4.77
Exercise Price, Upper Limit	$ 21
Number of Shares, Outstanding	237,349
Remaining Contractual Life (In Years), Outstanding	4 years 8 months 23 days
Aggregate Intrinsic Value, Outstanding	$ 0
Number of shares, Exercisable	215,428
Remaining Contractual Life (In Years), Exercisable	4 years 5 months 5 days
Aggregate Intrinsic Value, Exercisable	$ 0
$23.70 - $90.10 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price, Lower Limit	$ 23.70
Exercise Price, Upper Limit	$ 90.10
Number of Shares, Outstanding	43,293
Remaining Contractual Life (In Years), Outstanding	2 years 5 months 12 days
Aggregate Intrinsic Value, Outstanding	$ 0
Number of shares, Exercisable	43,293
Remaining Contractual Life (In Years), Exercisable	2 years 5 months 12 days
Aggregate Intrinsic Value, Exercisable	$ 0
$98.50 - $98.50 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price, Lower Limit	$ 98.50
Exercise Price, Upper Limit	$ 98.50
Number of Shares, Outstanding	2,500
Remaining Contractual Life (In Years), Outstanding	1 year 4 months 21 days
Aggregate Intrinsic Value, Outstanding	$ 0
Number of shares, Exercisable	2,500
Remaining Contractual Life (In Years), Exercisable	1 year 4 months 21 days
Aggregate Intrinsic Value, Exercisable	$ 0
$117.00 - $117.00 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price, Lower Limit	$ 117
Exercise Price, Upper Limit	$ 117
Number of Shares, Outstanding	114
Remaining Contractual Life (In Years), Outstanding	1 year 4 days
Aggregate Intrinsic Value, Outstanding	$ 0
Number of shares, Exercisable	114
Remaining Contractual Life (In Years), Exercisable	1 year 4 days
Aggregate Intrinsic Value, Exercisable	$ 0

Equity Incentive Plans - Summ60

Equity Incentive Plans - Summary of Unvested Share Units (Restricted Stock Units) (Detail) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at January 1, 2015, Number Of Shares	81,050
Granted, Number Of Shares	0
Released, Number Of Shares	(21,875)
Forfeited, Number Of Shares	(22,225)
Outstanding at December 31, 2015, Number Of Shares	36,950	81,050
Outstanding at January 1, 2015, Weighted Average Grant-Date Fair Value	$ 4.67
Granted, Weighted Average Grant-Date Fair Value	0	$ 0	$ 4.67
Released, Weighted Average Grant-Date Fair Value	4.67
Forfeited, Weighted Average Grant-Date Fair Value	4.67
Outstanding at December 31, 2015, Weighted Average Grant-Date Fair Value	$ 4.67	$ 4.67

Equity Incentive Plans - Author

Equity Incentive Plans - Authorized Shares of Common Stock for Issuance (Detail) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
2015 Plan and the 2015 Directors’ Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Authorized shares of common stock for issuance, Number of Shares	1,250,000
2005 Plan and the Directors’ Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Authorized shares of common stock for issuance, Number of Shares	175,000	158,751	2,319,812

Restructuring - Additional Info

Restructuring - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Sep. 30, 2015Employee	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges of long-lived assets		$ 8,591,000	$ 0
Additional cost of goods sold related to inventory		1,229,000
Prepayments to supplier for lower housing assembly		$ 1,024,000
Severance payment description		Each affected employee received (i) severance payments equal to three months of salary plus an additional amount equal to one week of salary for each year of Alexza service in excess of five years; and (ii) three months of paid medical insurance premiums and outplacement services, or in total, the Severance Package.
Employee Severance [Member]
Restructuring Cost And Reserve [Line Items]
Number of employees eliminated | Employee	33
Employee Severance [Member] | If Employees Position is Not Eliminated [Member]
Restructuring Cost And Reserve [Line Items]
Severance package cost		$ 2,718,000	$ 0	$ 0
Aggregate cost of severance package		$ 1,474,000

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - USD ($)

Mar. 21, 2016

Mar. 07, 2016

Dec. 15, 2015

Sep. 28, 2015

Sep. 15, 2015

Mar. 23, 2016

Feb. 29, 2016

Mar. 31, 2014

Dec. 31, 2015

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Sep. 30, 2015

Subsequent Event [Line Items]

Non-recourse notes issued

$ 45,000,000

$ 45,000,000

Number of common shares, callable by warrants issued in the aggregate stock and warrants sale

345,661

345,661

345,661

Amortization of debt discount

$ 74,000

Estimated life of the warrant

5 years

5 years

Interest expense amortization period

5 years

5 years

5 years

Proceeds from financing obligations

$ 2,914,000

$ 50,830,000

$ 15,000,000

Common stock, shares issued

19,577,729

19,577,729

19,404,697

Product sales

$ 2,355,000

$ 2,564,000

$ 874,000

Subsequent Event [Member] | NASDAQ Capital Market [Member]

Subsequent Event [Line Items]

Minimum market value requirement

$ 35,000,000

Number of minimum consecutive business days of market capitalization for listed securities requirements

10 days

Number of days to evidence compliance with minimum bid price requirement

180 days

Minimum bid price requirement

$ 1

NASDAQ's listed securities requirement, description

On March 7, 2016, the Panel issued a determination granting our request for the continued listing of our common stock on The NASDAQ Capital Market. Our continued listing on The NASDAQ Capital Market is subject to, among other things, evidence of our compliance with the minimum $35,000,000 market value of listed securities requirement by June 14, 2016. In order to satisfy the market value of listed securities requirement, we must evidence a market capitalization of at least $35,000,000 for a minimum of 10 consecutive business days on or before June 14, 2016. We also remain subject to the 180-day period within which to evidence compliance with the minimum $1.00 bid price requirement, which does not expire until July 18, 2016.

Royalty Securitization Financing [Member]

Subsequent Event [Line Items]

Debt instrument, interest due

$ 2,756,000

$ 2,756,000

Renewal period

thirty day renewing periods through June 15, 2016

Debt instrument issued date

2014-03

Amortization of debt discount

$ 74,000

Ferrer Note [Member]

Subsequent Event [Line Items]

Proceeds from financing obligations

$ 3,000,000

Additional tranche to borrow

$ 1,000,000

Debt instrument interest rate

6.00%

Promissory note, due date

May 31, 2016

Common stock, shares issued

125,000

Ferrer Note [Member] | Maximum [Member]

Subsequent Event [Line Items]

Principal amount of promissory note

5,000,000

Ferrer Note [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Proceeds from financing obligations

$ 1,000,000

$ 1,000,000

Principal amount of the Ferrer Note outstanding

$ 4,000,000

Ferrer Note [Member] | Promissory Note [Member]

Subsequent Event [Line Items]

Debt instrument interest rate

600.00%

Ferrer Note [Member] | Promissory Note [Member] | Maximum [Member]

Subsequent Event [Line Items]

Principal amount of promissory note

$ 5,000,000

Teva Note [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Common stock shares issued upon debt conversion

2,172,886

Reduction in outstanding balance of Notes

$ 5,000,000

Outstanding balance of notes

$ 20,000,000

Frequency of periodic payment

Four

Annual consecutive payments amount

$ 5,000,000

Product sales

$ 50,000,000

401(k) Plan - Additional Inform

401(k) Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]
Employee contribution matched	$ 36,000	$ 128,000

Income Taxes - Summarized Repor

Income Taxes - Summarized Report of Domestic Federal Statutory Tax Rates to Loss before Income Taxes from Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal tax benefit at statutory rate	$ (7,246)	$ (12,489)	$ (13,469)
State tax benefit net of federal effect	(1,243)	(2,143)	(2,311)
Research and development credits	(456)	(560)	(532)
Other permanent differences	8	2	14
Share-based compensation	678	414	650
Adjustment to basis in subsidiary	(10,808)	(3,246)	15,899
Change in valuation allowance	17,140	16,946	(357)
Reduction of deferred tax asset attributed to expired net operating loss carryforward	1,927	1,076	106
Other	0	0	0
Total	$ 0	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Line Items]
Effective tax rate of deferred tax assets	40.00%
(Decreased) increase in valuation allowances	$ 14,558,000	$ 16,645,000	$ (272,000)
Deferred tax asset	$ 0
Minimum [Member]
Income Tax Disclosure [Line Items]
Various tax years	2,000
Maximum [Member]
Income Tax Disclosure [Line Items]
Various tax years	2,015
State research and development [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 261,431,000
Net operating loss and tax credit carryforwards expiration date	2,016
Deferred tax assets attributable to stock-based compensation deductions excess of book expense	$ 1,393,000
Research [Member] | State research and development [Member]
Income Tax Disclosure [Line Items]
Research and development tax credit carryforwards	8,319,000
Internal Revenue Service (IRS)[Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	368,164,000
Internal Revenue Service (IRS)[Member] | Research [Member]
Income Tax Disclosure [Line Items]
Research and development tax credit carryforwards	$ 10,731,000
Net operating loss and tax credit carryforwards expiration date	2,020

Income Taxes - Report of Compan

Income Taxes - Report of Company's Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Federal and state net operating loss carryforwards	$ 139,874	$ 130,011
Federal and state research and development credit carryforwards	16,222	15,536
Accrued liabilities	3,460	7,177
Properties and Equipment	7,740	0
Capitalized research and development costs	16,263	16,027
Other	1,842	2,092
Total deferred tax assets	185,401	170,843
Valuation allowance	(185,401)	(170,843)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Reconciliation R

Income Taxes - Reconciliation Report of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Beginning Balance	$ 2,932	$ 2,819	$ 3,014
Additions based on tax positions taken during a prior period	87	0	0
Reductions based on tax positions taken during a prior period	0	0	(231)
Additions based on tax positions taken during the current period	95	113	36
Reductions based on tax positions taken during the current period	0	0	0
Reductions related to settlement of tax matters	0	0	0
Reductions related to a lapse of applicable statute of limitations	0	0	0
Ending Balance	$ 3,114	$ 2,932	$ 2,819

Quarterly Results - Summary of

Quarterly Results - Summary of Quarterly Results (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 673	$ 1,773	$ 1,875	$ 705	$ 1,454	$ 457	$ 1,484	$ 2,166	$ 5,026	$ 5,561	$ 47,839
Loss from operations	(9,983)	(7,597)	(9,441)	(13,003)	(7,264)	(10,040)	(11,349)	(8,803)	(40,024)	(37,456)	1,770
Net loss	$ (3,018)	$ (5,438)	$ (12,450)	$ (404)	$ (6,707)	$ (13,328)	$ (5,962)	$ (10,735)	$ (21,310)	$ (36,732)	$ (39,615)
Basic and diluted net loss per share	$ (0.15)	$ (0.27)	$ (0.63)	$ (0.02)	$ (0.35)	$ (0.77)	$ (0.34)	$ (0.62)	$ (1.08)	$ (2.07)	$ (2.38)

Quarterly Results - Additional

Quarterly Results - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015
Interim Reporting [Line Items]
Non cash impairment charges		$ 10,844,000
Non operating and non cash gain		$ 27,132,000
Three Quarters Ended September 30, 2014 [Member]
Interim Reporting [Line Items]
Share-based compensation expense reversal	$ 1,009,000
Three Years Ended December 31, 2013 [Member]
Interim Reporting [Line Items]
Share-based compensation expense reversal	$ 1,191,000